1964–1968
B.A., Biochemistry — Princeton University, Princeton, NJ
Bonner JT, Barkely DS, Hall EM, Konijn TM, Mason JW, O'Keefe G, Wolfe PB. Acrasin, acrasinase, and the sensitivity to acrasin in dictyostelium discoideum. Dev Biol 20:72–87, 1969.
Mason JW, Rasmussen H, Dibella F. 3'5' AMP and Ca2+ in slime mold aggregation. Exp Cell Res 67:156–160, 1971.
Rider AK, Copeland JG, Hunt SA, Mason JW, Specter MJ, Winkle RA, Bieber CP, Billingham ME, Dong EJ, Griepp RB, Schroeder JS, Stinson EB, Harrison DC, Shumway NE. The status of cardiac transplantation. Circulation 52:531–539, 1975.
Mason JW, Stinson EB, Hunt SA, Schroeder JS, Rider AK. Infections after cardiac transplantation: Relation to rejection therapy. Ann Intern Med 85:69–72, 1976.
Mason JW, Stinson EB, Harrison DC. Autonomic nervous system and arrhythmias: Studies in the transplanted denervated human heart. Cardiology 61:75–87, 1976.
Mason JW, Rossen RM, Colby T, Harrison DC. Bacterial endocarditis after cardiac catheterization. Chest 70:293–296, 1976.
Billingham ME, Bristow MR, Mason JW, Friedman M. Endomyocardial biopsy findings in adriamycin-treated patients. Proc Am Soc Clin Oncology 17:281, 1976.
Ricci DR, Rider AK, Mason JW. Recurrent tachyarrhythmia associated with a bifocal demand pacemaker. Chest 72:120–123, 1977.
Copeland JG, Griepp RB, Bieber CP, Billingham ME, Schroeder JS, Hunt SA, Mason JW, Stinson EB, Shumway NE. Successful retransplantation of the human heart. J Thorac Cardiovasc Surg 73:242–247, 1977.
Mason JW, Winkle RA, Rider AK, Stinson EB, Harrison DC. The electrophysiologic effects of quinidine in the transplanted human heart. J Clin Invest 59:481–489, 1977.
Mason JW, Winkle RA, Ingels HB, Daughters GT, Harrison DC, Stinson EB. Hemodynamic effects of intravenously administered quinidine on the transplanted human heart. Am J Cardiol 40:99–104, 1977.
Mason JW, Myers RW, Alderman EL, Stinson EB, Goris ML, Kriss JP. Technetium-99m pyrophosphate myocardial uptake in patients with stable angina pectoris. Am J Cardiol 40:1–5, 1977.
Billingham ME, Bristow MR, Glatstein E, Mason JW, Masek MA, Daniels JR. Adriamycin cardiotoxicity: Endomyocardial biopsy evidence of enhancement by irradiation. Am J Surg Pathol 1:17–23, 1977.
Mason JW, Billingham ME, Friedman JP. Methysergide-induced heart disease: A case of multivalvular and myocardial fibrosis. Circulation 56:889–890, 1977.
Stemple DR, Hall RJ, Mason JW, Harrison DC. Electrophysiologic effects of edrophonium in the innervated and the transplanted denervated human heart. Br Heart J 40:644–649, 1978.
Anderson JL, Mason JW. Successful treatment by overdrive pacing of recurrent quinidine syncope due to ventricular tachycardia. Am J Med 64:715–718, 1978.
Mason JW, Winkle RA, Meffin PJ, Harrison DC. Electrophysiologic effects of acebutolol. Br Heart J 40:35–40, 1978.
Mason JW, Spector MJ, Ingels NB, Daughters GT, Ferris AC, Alderman EL. Haemodynamic effects of acebutolol. Br Heart J 40:29–34, 1978.
Bristow MR, Mason JW, Billingham ME, Daniels JR. Doxorubicin cardiomyopathy: Evaluation by phonocardiography, endomyocardial biopsy, and cardiac catheterization. Ann Intern Med 88:168–175, 1978.
Anderson JL, Mason JW, Winkle RA, Meffin PJ, Fowles RE, Peters F, Harrison DC. Clinical electrophysiologic effects of tocainide. Circulation 57:685–691, 1978.
Mason JW. Techniques for right and left ventricular endomyocardial biopsy. Am J Cardiol 41:887–892, 1978.
Ingham RE, Mason JW, Rossen RM, Goodman DJ, Harrison DC. Electrophysiologic findings in patients with idiopathic hypertrophic subaortic stenosis. Am J Cardiol 41:811–816, 1978.
Billingham ME, Mason JW, Bristow MR, Daniels JR. Anthracycline cardiomyopathy monitored by morphological changes. Cancer Treat Rep 62:865–872, 1978.
Mason JW, Bristow MR, Billingham ME, Daniels JR. Invasive and noninvasive methods of assessing adriamycin cardiotoxicity in man: Superiority of histopathologic assessment using endomyocardial biopsy. Cancer Treat Rep 62:857–864, 1978.
Bristow MR, Billingham ME, Mason JW, Daniels JR. Clinical spectrum of anthracycline antibiotic cardiotoxicity. Cancer Treat Rep 62:873–880, 1978.
Benjamin RS, Mason JW, Billingham ME. Cardiac toxicity of adriamycin-DNA complex and rubidazone: Evaluation by electrocardiogram and endomyocardial biopsy. Cancer Treat Rep 62:935–939, 1978.
Ricci DR, Orlick AE, Reitz BA, Mason JW, Stinson EB, Harrison DC. Depressant effect of digoxin on atrioventricular conduction in man. Circulation 57:898–903, 1978.
Lorell B, Alderman EL, Mason JW. Cardiac sarcoidosis: Diagnosis with endomyocardial biopsy and treatment with corticosteroids. Am J Cardiol 42:143–146, 1978.
Bristow MR, Thompson PD, Martin RP, Mason JW, Billingham ME, Harrison DC. Early anthracycline cardiotoxicity. Am J Med 65:823–832, 1978.
Mason JW, Koch FH, Billingham ME, Winkle RA. Cardiac biopsy evidence for a cardiomyopathy associated with symptomatic mitral valve prolapse. Am J Cardiol 42:557–562, 1978.
Mason JW, Winkle RA. Electrode-catheter arrhythmia induction in the selection and assessment of antiarrhythmic drug therapy for recurrent ventricular tachycardia. Circulation 58:971–985, 1978.
Harrison DC, Mason JW, Schroeder JS, Stinson EB. Effects of cardiac denervation on cardiac arrhythmias and electrophysiology. Br Heart J 40(suppl):17–23, 1978.
Sami M, Mason JW, Peters F, Harrison DC. Clinical electrophysiologic effects of encainide, a newly developed antiarrhythmic agent. Am J Cardiol 44:526–532, 1979.
Harrison DC, Mason JW. Effects of catecholamines and adrenergic innervation on cardiac conduction and arrhythmias. J R Soc Med Symp 8:17–30, 1979.
Motta J, Guilleminault C, Billingham ME, Barry WH, Mason JW. Cardiac abnormalities in myotonic dystrophy: Electrophysiologic and histopathologic studies. Am J Med 67:467–473, 1979.
Sami M, Mason JW, Oh G, Harrison DC. Canine electrophysiology of encainide, a new antiarrhythmic drug. Am J Cardiol 43:1149–1154, 1979.
Mason JW, Strefling A. Small vessel disease of the heart resulting in myocardial necrosis and death despite angiographically normal coronary arteries. Am J Cardiol 44:171–176, 1979.
Mason JW, Myers RW, Goris ML, Doherty P, Alderman EL, Kriss JP. Reliability and reproducibility of interpretation of technetium 99m pyrophosphate myocardial scintigrams. Clin Cardiol 2:446–449, 1979.
Mason JW. Evidence for a unidirectional retrograde communication between distal His bundle and the atria. Br Heart J 43:600–604, 1980.
Mason JW. Overdrive suppression in the transplanted heart: Effect of the autonomic nervous system on human sinus node recovery. Circulation 62:688–696, 1980.
Mason JW, Billingham ME, Ricci DR. Treatment of acute inflammatory myocarditis assisted by endomyocardial biopsy. Am J Cardiol 45:1037–1044, 1980.
Mason JW. Repetitive beating after single ventricular extrastimuli: Incidence and prognostic significance in patients with recurrent ventricular tachycardia. Am J Cardiol 45:1126–1131, 1980.
Mason JW, Billingham ME. Endomyocardial biopsy in modern practice. J Cardiovasc Med 5:683–691, 1980.
Mason JW, Winkle RA. Accuracy of the ventricular tachycardia induction study for predicting long-term efficacy and inefficacy of antiarrhythmic drugs. N Engl J Med 303:1073–1077, 1980.
Winkle RA, Mason JW, Harrison DC. Tocainide for drug-resistant ventricular arrhythmias: Efficacy, side effects, and lidocaine responsiveness for predicting tocainide success. Am Heart J 100:1031–1036, 1980.
Griffin JC, Mason JW, Calfee RA. Clinical use of an implantable automatic tachycardia-terminating pacemaker. Am Heart J 100:1093–1096, 1980.
Harrison DC, Winkle RA, Sami M, Mason JW. Encainide: A new and potent antiarrhythmic agent. Am Heart J 100:1046–1054, 1980.
Mason JW, Peters FA. Antiarrhythmic efficacy of encainide in patients with refractory recurrent ventricular tachycardia. Circulation 63:670–675, 1981.
McKillop JH, McDougall IR, Goris ML, Mason JW, Reitz BA. Failure to diagnose cardiac transplant rejection with Tc-99m-Pyp images. Clin Nucl Med 6:375–377, 1981.
Griffin JC, Mason JW, Ross DL, Calfee RV. The treatment of ventricular tachycardia using an automatic tachycardia terminating pacemaker. PACE 4:582–588, 1981.
Bristow MR, Mason JW, Billingham ME, Daniels JR. Dose-effect and structure-function relationships in doxorubicin cardiomyopathy. Am Heart J 102:709–718, 1981.
Winkle RA, Mason JW, Griffin JC, Ross DL. Malignant ventricular tachyarrhythmias associated with the use of encainide. Am Heart J 102:857–864, 1981.
Jaillon P, Rubenson D, Peters F, Mason JW, Winkle RA. Electrophysiologic effects of N-acetylprocainamide in human beings. Am J Cardiol 47:1134–1139, 1981.
Mason JW, Stinson EB, Winkle RA, Oyer PE. Mechanisms of ventricular tachycardia: Wide, complex ignorance. Am Heart J 102:1083–1097, 1981.
Fowles RE, Mason JW. Myocarditis and endomyocardial biopsy. Cardiovasc Rev and Rep 2:1153–1155, 1981.
Mason JW, Stinson EB, Winkle RA, Oyer PE, Griffin JC, Ross DL. Relative efficacy of blind left ventricular aneurysm resection for the treatment of recurrent ventricular tachycardia. Am J Cardiol 49:241–248, 1982.
Mitchell LB, Jutzy KR, Lewis SJ, Schroeder JS, Mason JW. Intracardiac electrophysiologic study of intravenous diltiazem and combined diltiazem-digoxin in patients. Am Heart J 103:57–66, 1982.
Anderson KP, Stinson EB, Mason JW. Surgical exclusion of focal paroxysmal atrial tachycardia. Am J Cardiol 49:869–874, 1982.
Mason JW, Swerdlow CD, Winkle RA, Griffin JC, Ross DL, Keefe DL, Clusin WT. Programmed ventricular stimulation in predicting vulnerability to ventricular arrhythmias and their response to antiarrhythmic therapy. Am Heart J 103(Part 2):633–637, 1982.
Mason JW, Stinson EB, Winkle RA, Griffin JC, Oyer PE, Ross DL, Derby G. Surgery for ventricular tachycardia: Efficacy of left ventricular aneurysm resection compared with operation guided by electrical activation mapping. Circulation 65:1148–1155, 1982.
Melvin KR, Mason JW. Endomyocardial biopsy: Its history, techniques and current indications. J Can Med Assoc 126:1381–1386, 1982.
Bristow MR, Lopez MB, Mason JW, Billingham ME, Winchester MA. Efficacy and cost of cardiac monitoring in patients receiving doxorubicin. Cancer 50:32–41, 1982.
Freedman RA, Rothman MT, Mason JW. Recurrent ventricular tachycardia induced by an atrial synchronous ventricular-inhibited pacemaker. PACE 5:490–494, 1982.
Ross DL, Sze DY, Keefe DL, Swerdlow CD, Echt DS, Griffin JC, Winkle RA, Mason JW. Antiarrhythmic drug combinations in the treatment of ventricular tachycardia: Efficacy and electrophysiologic effects. Circulation 66:1205–1210, 1982.
Echt DS, Berte LE, Clusin WT, Samuelsson RG, Harrison DC, Mason JW. Prolongation of the human cardiac monophasic action potential by sotalol. Am J Cardiol 50:1082–1086, 1982.
Fowles RE, Mason JW. Endomyocardial biopsy. Ann Intern Med 97:885–894, 1982.
Swerdlow CD, Blum J, Winkle RA, Griffin JC, Ross DL, Mason JW. Decreased incidence of antiarrhythmic drug efficacy at electrophysiologic study associated with use of a third extrastimulus. Am Heart J 104:1004–1010, 1982.
Rasmussen K, Winkle R, Ross D, Griffin J, Peters F, Mason J. Antiarrhythmic efficacy of amiodarone in recurrent ventricular tachycardia evaluated by multiple electrophysiological and ambulatory ECG recordings. Acta Med Scand 212:367–374, 1982.
Mason JW, Hondeghem LM, Katzung BG. Amiodarone blocks inactivated cardiac sodium channels. Pflugers Arch 396:79–81, 1983.
Anderson KP, Stinson EB, Derby GC, Oyer PE, Mason JW. Vulnerability of patients with obstructive hypertrophic cardiomyopathy to ventricular arrhythmia induction in the operating room: Analysis of 17 patients. Am J Cardiol 55:811–816, 1983.
Swerdlow CD, Gong G, Echt DS, Winkle RA, Griffin JC, Ross DL, Mason JW. Clinical factors predicting successful electrophysiologic-pharmacologic study in patients with ventricular tachycardia. J Am Coll Cardiol 1:409–416, 1983.
Mason JW, Swerdlow CD, Mitchell LB. Efficacy of verapamil in chronic, recurrent ventricular tachycardia. Am J Cardiol 51:1614–1617, 1983.
Swerdlow CD, Winkle RA, Mason JW. Determinants of survival in patients with ventricular tachyarrhythmias. N Engl J Med 308:1436–1442, 1983.
Swerdlow CD, Yu JO, Jacobson E, Mann S, Winkle RA, Griffin JC, Ross DL, Mason JW. Safety and efficacy of intravenous quinidine. Am J Med 75:36–42, 1983.
Fogoros RN, Anderson KP, Winkle RA, Swerdlow CD, Mason JW. Amiodarone: Clinical efficacy and toxicity in 96 patients with recurrent, drug refractory arrhythmias. Circulation 68:88–94, 1983.
Swerdlow CD, Winkle RA, Mason JW. Prognostic significance of the number of induced ventricular complexes during assessment of therapy for ventricular tachyarrhythmias. Circulation 68:400–405, 1983.
Winkle RA, Bach SM, Echt DS, Swerdlow CD, Imran M, Mason JW, Oyer PE, Stinson EB. The automatic implantable defibrillator: Local ventricular bipolar sensing to detect ventricular tachycardia and fibrillation. Am J Cardiol 52:265–270, 1983.
Connolly SJ, Kates RE, Lebsack CS, Echt DS, Mason JW, Winkle RA. Clinical efficacy and electrophysiology of oral propafenone for ventricular tachycardia. Am J Cardiol 52:1208–1213, 1983.
Echt DS, Griffin JC, Ford AJ, Knutti JW, Feldman RC, Mason JW. Nature of inducible ventricular tachyarrhythmias in a canine chronic myocardial infarction model. Am J Cardiol 52:1127–1132, 1983.
Anderson KP, Swerdlow CD, Mason JW. Entrainment of ventricular tachycardia. Am J Cardiol 53:335–340, 1984.
Mitchell LB, Mason JW, Scheinman MM, Winkle RA, Burchell HB. Recordings of basal ventricular preexcitation from electrode catheters in patients with accessory atrioventricular connections. Circulation 69:233–241, 1984.
Connolly SJ, Mitchell LB, Swerdlow CD, Mason JW, Winkle RA. Clinical efficacy and electrophysiology of imipramine for ventricular tachycardia. Am J Cardiol 53:516–521, 1984.
Keren A, Gillis AM, Freedman RA, Baldwin JC, Billingham ME, Stinson EB, Simson MB, Mason JW. Heart transplant rejection monitored by signal-averaged electrocardiography in patients receiving cyclosporine. Circulation 70(suppl I):I-124–129, 1984.
Mason JW, Hondeghem LM, Katzung BG. Block of inactivated sodium channels and of depolarization-induced automaticity in guinea pig papillary muscle by amiodarone. Circ Res 55:277–285, 1984.
Freedman RA, Swerdlow CD, Echt DS, Winkle RA, Soderholm-Diffatte V, Mason JW. Facilitation of ventricular tachyarrhythmia induction by isoproterenol. Am J Cardiol 54:765–770, 1984.
Mason JW, Hondeghem LM. Quinidine: The electrophysiology, pharmacology, and clinical efficacy of classic cardiac antiarrhythmic agents. Ann NY Acad Sci 432:162–176, 1984.
Bhandari AK, Scheinman MM, Morady F, Svinarich J, Mason J, Winkle R. Efficacy of left cardiac sympathectomy in the treatment of patients with the long QT syndrome. Circulation 70:1018–1023, 1984.
Anderson KP, Mason JW. Transient entrainment and interruption of ventricular tachycardia with rapid atrial pacing — II. J Am Coll Cardiol 4(5):1067, 1984.
Bhandari A, Shapiro W, Morady F, Shen D, Mason J, Scheinman M. Electrophysiologic testing in patients with the long QT syndrome. Circulation 71:63–71, 1985.
Echt DS, Shapiro M, Trusso J, Mason JW, Winkle RA. Treatment with oral lorcainide in patients with sustained ventricular tachycardia and fibrillation. Am Heart J 109:28–33, 1985.
Freedman RA, Gillis AM, Keren A, Soderholm-Difatte V, Mason JW. Signal-averaged electrocardiographic late potentials in patients with ventricular fibrillation or ventricular tachycardia: Correlation with clinical arrhythmia and electrophysiologic study. Am J Cardiol 55:1350–1353, 1985.
Mason JW, Stinson EB, Oyer PE, Winkle RA, Hunt S, Anderson KP, Derby GC. The mechanisms of ventricular tachycardia in humans determined by intraoperative recording of the electrical activation sequence. Int J Cardiol 8:163–172, 1985.
Teichman SL, Waspe LE, Matos JA, Kim SG, Fisher JD and participating members of a multicenter bethanidine study. Bethanidine sulfate: Efficacy in prevention of ventricular tachyarrhythmias during programmed stimulation. Report of a multicenter study of 56 patients. J Am Coll Cardiol 6:510–517, 1985.
Nanas JN, Mason JW, Yoshiyuki T, Chiang BY, Olsen DB. Hemodynamic effects of an abdominal aortic counterpulsation device designed for chronic use in graded heart failure. Life Support Systems 2:245–249, 1985.
Nanas JN, Mason JW, Taenaka Y, Olsen DB. Comparison of an implanted abdominal aortic counterpulsation device with the intraaortic balloon pump in a heart failure model. J Am Coll Cardiol 7:1028–1035, 1986.
Mason JW. Basic and clinical cardiac electrophysiology of encainide. Am J Cardiol 58:18c–24c, 1986.
Anderson JL, Askins JC, Gilbert EM, Miller RH, Keefe DL, Somberg JC, Freedman RA, Haft LR, Mason JW, Lessem JN. Multicenter trial of sotalol for suppression of frequent, complex ventricular arrhythmias: A double-blind, randomized, placebo-controlled evaluation of two doses. J Am Coll Cardiol 8:752–762, 1986.
Anderson KP, Stinson EB, Block PJ, Derby G, Oyer PE, Ross DL, Popp RL, Mason JW. Epicardial mapping in patients with hypertrophic cardiomyopathy. J Appl Cardiol 1:285–307, 1986.
Swerdlow CD, Mason JW, Stinson EB, Oyer P, Winkle R, Derby GC. Results of operations for VT in 105 patients. J Thorac Cardiovasc Surg 92:105–113, 1986.
Freedman RA, Anderson KP, Green LS, Mason JW. Effect of erythromycin on ventricular arrhythmias and ventricular repolarization in idiopathic long QT syndrome. Am J Cardiol 59:168–169, 1987.
Mason JW, Anderson KP, Freedman RA. Techniques and criteria in electrophysiologic study of ventricular tachycardia. Circulation 75(suppl III):III-125–130, 1987.
Rahimtoola SH, Zipes DP, Akhtar M, Burchell H, Mason JW, Myerburg R, O'Rourke R, Ruskin J, Schlant R, Surawicz B. Consensus statement of the conference on the state of the art of electrophysiologic testing in the diagnosis and treatment of patients with cardiac arrhythmias. Circulation 75(suppl III):III-3–11, 1987.
Mason JW. Amiodarone. N Engl J Med 316:455–466, 1987.
Gilbert EM, Bristow MR, Mason JW. Acute hemodynamic response to low dose enoximone (MDL 17,043): An oral dose-range study. Am J Cardiol 60:57C–62C, 1987.
Ross DL, Davis KB, Pettinger MB, Alderman EL, Killip T, Mason JW. Features of cardiac arrest episodes with and without acute myocardial infarction (CASS). Am J Cardiol 60:1219–1224, 1987.
Anderson JL, Fowles RE, Unverferth DV, Mason JW. Immunosuppressive therapy of myocardial inflammatory disease. Initial experience and future trials to define indications for therapy. Eur Heart J 8(Suppl J):263–266, 1987.
Freedman RA, Swerdlow CD, Soderholm-Difatte V, Mason JW. Prognostic significance of arrhythmia inducibility or noninducibility at initial electrophysiologic study in survivors of cardiac arrest. Am J Cardiol 61:578–582, 1988.
Phibbs B, Fleming T, Ewy GA, Butman S, Ambrose J, Gorlin R, Orme E, Mason J. Frequency of normal coronary arteriograms in three academic medical centers and one community hospital. Am J Cardiol 62:472–474, 1988.
Freedman RA, Swerdlow CD, Soderholm-Difatte V, Mason JW. Clinical predictors of arrhythmia inducibility in survivors of cardiac arrest: Importance of gender and prior myocardial infarction. J Am Coll Cardiol 12:973–978, 1988.
O'Connell JB, Mason JW. Immunosuppressive therapy in experimental and clinical myocarditis. Pathol Immunopathol Res 7:292–304, 1988.
Nanas JN, Mason JW, Riebman JB, Charitos CE, Burns GL, Olsen DB. Preclinical evaluation of the abdominal aortic counterpulsation device. Am Heart J 116:1003–1008, 1988.
Orme EC, Wray RB, Barry WH, Krueger SK, Mason JW. Comparison of three techniques for percutaneous balloon aortic valvuloplasty of aortic stenosis in adults. Am Heart J 117:11–17, 1989.
Orme EC, Wray RB, Mason JW. Balloon mitral valvuloplasty via retrograde left atrial catheterization. Am Heart J 117:681–683, 1989.
Mason JW, Investigators. The ESVEM trial: Electrophysiologic study versus electrocardiographic monitoring for selection of antiarrhythmic therapy of ventricular tachyarrhythmias. Circulation 79:1354–1360, 1989.
O'Connell JB, Mason JW. Therapeutic implications of immune mechanisms in myocarditis. Spring Semin Immunopathol 11:43–49, 1989.
ACC/AHA Subcommittee to Assess Clinical Intracardiac Electrophysiologic Studies. Guidelines for clinical intracardiac electrophysiologic studies. J Am Coll Cardiol 14:1827–1842, 1990.
O'Connell JB, Mason JW. The applicability of results of streamlined trials to clinical practice: The myocarditis treatment trial. Stat Med 9:193–197, 1990.
Freedman RA, Steinberg JS, for the ESVEM Investigators. Selective prolongation of QRS late potentials by sodium channel blocking antiarrhythmic drugs: Relation to slowing of ventricular tachycardia. J Am Coll Cardiol 17:1017–1025, 1991.
Narahara KA, The Western Enoximone Study Group. Oral enoximone therapy in chronic heart failure: A placebo-controlled randomized trial. Am Heart J 121:1471–1479, 1991.
ACC/AHA Task Force — Dreifus LS, Fisch C, Gillette PC, Griffin JC, Mason JW, Parsonnet V. Guidelines for implantation of cardiac pacemakers and antiarrhythmia devices. J Am Coll Cardiol 18:1–13, 1991 and Circulation 84:455–467, 1991.
Anastasiou-Nana MI, Menlove RL, Nanas JN, Mason JW. Spontaneous variability of ventricular arrhythmias in patients with chronic heart failure. Am Heart J 122:1007–1015, 1991.
Flowers NC, Abildskov JA, Armstrong WF, et al. Recommended guidelines for training in adult clinical cardiac electrophysiology. ACC Policy Statement. J Am Coll Cardiol 18:637–640, 1991.
Bigger JT Jr, Fleiss JL, Rolnitzky LM, Steinman RC, with data contributed by the CAPS and ESVEM Investigators. Stability over time of heart period variability in patients with previous myocardial infarction and ventricular arrhythmias. Am J Cardiol 69:718–723, 1992.
Sharp SD, Mason JM, Bray BE. Comparison of ST depression recorded by Holter monitors and 12-lead electrocardiograms during coronary angiography and exercise testing. J Electrocardiol 25:323–331, 1992.
The ESVEM Investigators. Determinants of predicted efficacy of antiarrhythmic drugs in the Electrophysiologic Study Versus Electrocardiographic Monitoring trial. Circulation 87:323–329, 1993.
Mason JW for the ESVEM Investigators. A comparison of electrophysiologic testing with Holter monitoring to predict antiarrhythmic-drug efficacy for ventricular tachyarrhythmias. N Engl J Med 329:445–451, 1993.
Mason JW for the ESVEM Investigators. A comparison of seven antiarrhythmic drugs in patients with ventricular arrhythmias. N Engl J Med 329:452–458, 1993.
Mason JW. Implications of the ESVEM trial for use of antiarrhythmic drugs that prolong cardiac repolarization. Am J Cardiol 72:59F–61F, 1993.
Nanas JN, Mason JW. Pharmacokinetics and regional electrophysiologic effects of intracoronary amiodarone administration. Circulation 91:451–461, 1995.
Omoigui NA, Marcus FI, Mason JW, Hlatky MA. Cost of initial therapy in the Electrophysiologic Study Versus Electrocardiographic Monitoring trial (ESVEM). Circulation 91:1070–1076, 1995.
Reiter MJ, Mann DE, Reiffel JE, Hahn E, Hartz V, and the ESVEM Investigators. Significance and incidence of concordance of drug efficacy predictions by Holter recording and electrophysiologic study in the ESVEM trial. Circulation 91:1988–1995, 1995.
Anderson KP, Walker R, Dustman T, Fuller M, Mori M, for the ESVEM Investigators. Spontaneous sustained ventricular tachycardia in the ESVEM trial. J Am Coll Cardiol 26:489–496, 1995.
Mason JW, O'Connell JB, Herskowitz A, Rose NR, McManus BM, Billingham ME, Moon TE and the Myocarditis Treatment Trial Investigators. A clinical trial of immunosuppressive therapy for myocarditis. N Engl J Med 333:269–275, 1995.
Hahn EA, Hartz VL, Moon TE, O'Connell JB, Herskowitz A, McManus BM, Mason JW for the Myocarditis Treatment Trial Investigators. The myocarditis treatment trial: Design, methods and patient enrollment. Eur Heart J 16(Suppl O):162–167, 1995.
Cain ME, Anderson JL, Arnsdorf MF, Mason JW, Scheinman MM, Waldo AL. Signal-averaged electrocardiography. J Am Coll Cardiol 27:238–249, 1996.
Mason JW, Marcus FI, Bigger JT, Lazzara R, Reiffel JA, Reiter MJ, Mann D. A summary and assessment of the findings and conclusions of the ESVEM trial. Prog Cardiovasc Dis 38:347–358, 1996.
Reiffel JA, Reiter MJ, Freedman RA, Mann D, Huang SKS, Hahn E, Hartz V, Mason JW, and the ESVEM Investigators. Influence of Holter monitor and electrophysiologic study methods and efficacy criteria on the outcome of patients with ventricular tachycardia and ventricular fibrillation in the ESVEM trial. Prog Cardiovasc Dis 38(5):359–370, 1996.
Mason JW. Immunopathogenesis and treatment of myocarditis: The United States myocarditis treatment trial. J Cardiac Failure 2(suppl 4):S173–S177, 1996.
Mason JW. Immunopathogenesis and treatment of myocarditis: The United States myocarditis treatment trial. In: Proceedings of the Fifth Antwerp-LaJolla-Kyoto Research Conference on Cardiac Function, Kyoto, Japan, December 13–15, 1995. J Cardiac Failure 2(suppl 4):S173–S177, 1996.
Compton SJ, Lux RL, Ramsey MR, Strelich KR, Sanguinetti MC, Green LS, Keating MT, Mason JW. Genetically defined therapy of inherited long-QT syndrome. Correction of abnormal repolarization by potassium. Circulation 94:1018–1022, 1996.
Smith SC, Ladenson JH, Mason JW, Jaffe AS. Elevations of cardiac troponin I associated with myocarditis. Experimental and clinical correlates. Circulation 95:163–168, 1997.
Hlatky MA, Boothroyd D, Johnstone I, Marcus FI, Hahn E, Hartz V, Mason JW, for the ESVEM Investigators. Long-term cost-effectiveness of alternative management strategies for patients with life-threatening ventricular arrhythmias. J Clin Epidemiol 50:185–193, 1997.
Reiter MJ, Karagounis LA, Mann DE, Reiffel JA, Hahn E, Hartz V, and the ESVEM Investigators. Reproducibility of drug efficacy predictions by Holter monitoring in the ESVEM trial. Am J Cardiol 79:315–322, 1997.
Caforio ALP, Goldman JH, Haven AJ, Baig MK, Libera LD, McKenna WJ and the Myocarditis Treatment Trial Investigators. Circulating cardiac-specific autoantibodies as markers of autoimmunity in clinical and biopsy-proven myocarditis. Eur Heart J 18:270–275, 1997.
Caruso AC, Marcus FI, Hahn EA, Hartz VL, Mason JW and the ESVEM Investigators. Predictors of arrhythmic death and cardiac arrest in the ESVEM trial. Circulation 96:1888–1892, 1997.
Anastasiou-Nana MI, Menlove RL, Mason JW for the Western Enoximone Study Group. Quantification of prevalence of asymptomatic ventricular arrhythmias in patients with heart failure. Annals Noninvasive Electrocardiology 2(4):346–353, 1997.
Mann DE, Hartz V, Hahn EA, Reiter MJ and the ESVEM Investigators. Effect of reproducibility of baseline arrhythmia induction on drug efficacy predictions and outcome in the ESVEM trial. Am J Cardiol 80:1448–1452, 1997.
Reiffel JA, Hahn E, Hartz V, Reiter MJ for the ESVEM Investigators. Sotalol for ventricular tachyarrhythmias: Beta-blocking and class III contributions, and relative efficacy versus class I drugs after prior drug failure. Am J Cardiol 79:1048–1053, 1997.
Mason JW, Hancock EW, Saunders DE, Schuger CD, Griffin JC, Kennedy HL, Buxton AE. American College of Cardiology Report on ECG Exam. J Am Coll Cardiol 29(2):466–8, 1997.
Lozano MD, Rubocki RJ, Wilson JE, McManus BM, Wisecarver JL, and the Myocarditis Treatment Trial Investigators. Human leukocyte antigen class II associations in patients with idiopathic dilated cardiomyopathy and myocarditis. J Cardiac Failure 3(2):97–103, 1997.
The BARI Investigators. Influence of diabetes on 5-year mortality and morbidity in a randomized trial comparing CABG and PTCA in patients with multivessel disease. Circulation 96:1761–1769, 1997.
Anastasiou-Nana MI, Karagounis LA, Anderson JL, Mason JW for the ESVEM Investigators. Spontaneous variability of ventricular ectopic activity in patients with sustained ventricular tachycardia and in survivors of cardiac arrest. Annals of Noninvasive Electrocardiology 3(3):194–201, 1998.
Sharma PP, Ott P, Hartz V, Mason JW, Marcus FI. Risk factors for tachycardia events due to antiarrhythmic drugs: Experience from the ESVEM trial. J Cardiovasc Pharmacol Therapeutics 3(4):269–274, 1998.
Olshansky B, Hahn EA, Hartz VL, Prater S, Mason JW, and the ESVEM Investigators. Clinical significance of syncope in the ESVEM trial. Am Heart J 137:878–886, 1999.
Mason JW, Borrowman T, Love R. Dilated cardiomyopathy: Problems in diagnosis and management. Chest 115:569–571, 1999.
Olshansky B, Hartz VL, Hahn EA, Mason JW, Douglas M, and the ESVEM Investigators. Location of death (in-hospital or out-of-hospital) and type of death (arrhythmic, cardiac, non-cardiac) after inducible sustained ventricular tachyarrhythmias following syncope, sustained ventricular tachycardia, or non-fatal cardiac arrest (the ESVEM trial). Am J Cardiol 86:846–51, 2000.
Kadish AH, Buxton AE, Kennedy HL, Knight BP, Mason JW, Schuger CD, Tracy CM. ACC/AHA clinical competence statement on electrocardiography and ambulatory electrocardiography. Circulation 104:3169–3178, 2001.
Kadish AH, Buxton AE, Kennedy HL, Knight BP, Mason JW, Schuger CD, Tracy CM. ACC/AHA clinical competence statement on electrocardiography and ambulatory electrocardiography. J Am Coll Cardiol 38:2091–100, 2001.
Etheridge SP, Compton SJ, Tristani-Firouzi M, Mason JW. A new oral therapy for long QT syndrome: Long-term oral potassium improves repolarization in patients with HERG mutations. J Am Coll Cardiol 42:1777–1782, 2003.
Lux RL, Gettes LS, Mason JW. Understanding proarrhythmic potential in therapeutic drug development: Alternate strategies for measuring and tracking repolarization. J Electrocardiol 39:S161–4, 2006.
Matsumori A, Shimada T, Chapman NM, Tracy SM, Mason JW. Myocarditis and heart failure associated with Hepatitis C virus infection. J Card Fail 12:293–298, 2006.
Kligfield P, Gettes LS, Bailey JJ, et al. Recommendations for the standardization and interpretation of the electrocardiogram: part I: the electrocardiogram and its technology. J Am Coll Cardiol 49:1109–1127, 2007.
Kligfield P, Gettes LS, Bailey JJ, et al. Recommendations for the standardization and interpretation of the electrocardiogram: part I: the electrocardiogram and its technology. Circulation 115:1306–1324, 2007.
Mason JW, Hancock EW, Gettes LS. Recommendations for the standardization and interpretation of the electrocardiogram: part II: electrocardiography diagnostic statement list. Heart Rhythm 4:413–419, 2007.
Mason JW, Hancock EW, Gettes LS, et al. Recommendations for the standardization and interpretation of the electrocardiogram: part II: electrocardiography diagnostic statement list. J Am Coll Cardiol 49:1128–1135, 2007.
Mason JW, Hancock EW, Gettes LS, et al. Recommendations for the standardization and interpretation of the electrocardiogram: part II: electrocardiography diagnostic statement list. Circulation 115:1325–1332, 2007.
Mason JW, Ramseth DJ, Chanter DO, Moon TE, Goodman DB, Mendzelevski B. Electrocardiographic reference ranges derived from 79,743 ambulatory subjects. J Electrocardiol 40:228–234, 2007.
Abascal VM, Zielke JC, Spady SD, Mason JW, Whayne TF. Synopsis of an epidemiologic study of a Kentucky county in the coronary valley. J Kentucky Med Assoc 106:527–531, 2008.
Strachan IG, Hughes NP, Poonawala MH, Mason JW, Tarassenko L. Automated QT analysis that learns from cardiologist annotations. Ann Noninvasive Electrocardiol 14:S9–21, 2009.
Wagner GS, Macfarlane P, Wellens H, et al. AHA/ACCF/HRS recommendations for the standardization and interpretation of the electrocardiogram: part VI: acute ischemia/infarction. J Am Coll Cardiol 53:1003–1115, 2009.
Wagner GS, Macfarlane P, Wellens H, et al. AHA/ACCF/HRS recommendations for the standardization and interpretation of the electrocardiogram: part VI: acute ischemia/infarction. Circulation 119:e262–70, 2009.
Hancock EW, Deal BJ, Mirvis DM, et al. AHA/ACCF/HRS recommendations for the standardization and interpretation of the electrocardiogram: part V: electrocardiogram changes associated with cardiac chamber hypertrophy. J Am Coll Cardiol 53:992–1002, 2009.
Hancock EW, Deal BJ, Mirvis DM, et al. AHA/ACCF/HRS recommendations for the standardization and interpretation of the electrocardiogram: part V: electrocardiogram changes associated with cardiac chamber hypertrophy. Circulation 119:e251–261, 2009.
Surawicz B, Childers R, Deal BJ, et al. AHA/ACCF/HRS recommendations for the standardization and interpretation of the electrocardiogram: part III: intraventricular conduction disturbances. J Am Coll Cardiol 53:976–981, 2009.
Surawicz B, Childers R, Deal BJ, et al. AHA/ACCF/HRS recommendations for the standardization and interpretation of the electrocardiogram: part III: intraventricular conduction disturbances. Circulation 119:e235–240, 2009.
Rautaharju PM, Surawicz B, Gettes LS, et al. AHA/ACCF/HRS recommendations for the standardization and interpretation of the electrocardiogram: part IV: the ST segment, T and U waves, and the QT interval. J Am Coll Cardiol 53:982–991, 2009.
Rautaharju PM, Surawicz B, Gettes LS, et al. AHA/ACCF/HRS recommendations for the standardization and interpretation of the electrocardiogram: part IV: the ST segment, T and U waves, and the QT interval. Circulation 119:e241–250, 2009.
Mason JW, Florian JA, Garnett CE, Moon TE, Selness DS, Spaulding RR. Pharmacokinetics and pharmacodynamics of three moxifloxacin dosage forms: Implications for blinding in active-controlled cardiac repolarization studies. J Clin Pharmacol 50:1249–59, 2010.
Darpo B, Lee SK, Moon TE, Sills N, Mason JW. Oritavancin, a new lipoglycopeptide antibiotic — results from a thorough QT study. J Clin Pharmacol 50:895–903, 2010.
Min SS, Turner JR, Nada A, et al. Evaluation of ventricular arrhythmias in early clinical pharmacology trials and potential consequences for later development. Am Heart J 159:716–29, 2010.
Matsumori A, Shimada T, Hattori H, Shimada M, Mason JW. Autoantibodies against cardiac troponin I in patients presenting with myocarditis. CVD Prev Control 6:41–46, 2011.
Mason JW, Selness DS, Moon TE, O'Mahony B, Donachie P, Howell J. Pharmacokinetics and repolarization effects of intravenous and transdermal granisetron. Clin Cancer Res 18:2913–21, 2012.
Christian JB, Finkle JK, Ky B, et al. Cardiac imaging approaches to evaluate drug-induced myocardial dysfunction. Am Heart J 164:846–55, 2012.
Mason JW, Moon TE. Use and cardiovascular safety of transdermal and other granisetron preparations in cancer management. Cancer Management Res 5:179–85, 2013.
Mason J, Moon T, O'Boyle E, Dietz A. A randomized, placebo-controlled, 4-period crossover, definitive QT study of the effects of APF530 exposure, high-dose intravenous granisetron and moxifloxacin on QTc prolongation. Cancer Management Res 6:181–190, 2014.
Mason JW, Schwertschlag US, Klutzaritz V, Canafax DM. Electrocardiographic and cardiovascular diagnostic characteristics of patients receiving chronic opioid therapy for pain. J Opioid Manag 10:103–110, 2014.
Rautaharju PM, Mason JW, Akiyama T. New age- and sex-specific criteria for QT prolongation based on rate correction formulas that minimize bias at the upper normal limits. Int J Cardiol 174:535–540, 2014.
Rautaharju PM, Mason JW, Akiyama T. Corrigendum to "New age- and sex-specific criteria for QT prolongation based on rate correction formulas that minimize bias at the upper normal limits." Int J Cardiol 178:299, 2015.
Mason JW. Timing of pre-dose baseline electrocardiograms in clinical trials: Increased sampling over a prolonged baseline period worsens variance of QTc. J Electrocardiol 47:716–720, 2014.
Johannesen L, Vicente J, Mason JW, et al. Differentiating drug-induced cardiac ion channel block on the electrocardiogram as related to torsade de pointes risk. Clin Pharmacol Ther 96:549–58, 2014.
Mason JW. Automated measurements for individualized heart rate correction of the QT interval. Clin Trials, January 2015. DOI: 10.1177/1740774514566332.
Rudd GD, Haverkamp W, Mason JW, Wenger T, Jay G, Hebert D, Doty P, Horstmann R. Lacosamide cardiac safety: Clinical trials of patients with partial-onset seizures. Acta Neurol Scand. DOI: 10.1111/ane.12414, 2015.
Vicente J, Johannesen L, Mason JW, Pueyo E, Stockbridge N, Strauss DG. Comprehensive T wave morphology assessment in a randomized clinical study of dofetilide, quinidine, ranolazine and verapamil. J Am Heart Assoc 4:e001615, 2015.
Johannesen L, Vicente J, Mason JW, et al. Late sodium current block for drug-induced long QT syndrome: Results from a prospective clinical trial. Clin Pharmacol Ther 99:214–223, 2015.
Mason JW, Badilini F, Vaglio M, Lux RL, Aysin B, Moon TE, Heinz B, Strachan I. A fundamental relationship between intraventricular conduction and heart rate. J Electrocardiol 49:362–370, 2016.
Mason JW, Moon TE. Moxifloxacin increases heart rate in humans. Antibiotics 2017, 6, 5. doi:10.3390/antibiotics6010005.
Johannesen L, Vicente J, Hosseini M, Mason JW, Dang Q, Stockbridge N, Strauss DG, Ugander M. Detection of drug-induced reverse use dependence and QT variability using postural maneuvers. Heart Rhythm 2015.
Vicente J, Johannesen L, Mason JW, Pueyo E, Stockbridge N, Strauss DG. Sex differences in drug-induced changes in ventricular repolarization. J Electrocardiol 48(6):1081–7, 2015.
Kontogiannis CD, Malliaras K, Kapelios CJ, Mason JW, Nanas JN. Continuous internal counterpulsation as a bridge to recovery in acute and chronic heart failure. World J Transplant 6:115–24, 2019.
Strauss DG, Vicente J, Johannesen L, et al. A common genetic variant risk score is associated with drug-induced QT prolongation and torsade de pointes risk: A pilot study. Circulation 135:1300–1310, 2017.
Vicente J, Johannesen L, Hosseini M, Mason JW, Sager PT, Pueyo E, Strauss DG. Electrocardiographic biomarkers for detection of drug-induced late sodium current block. PLOS ONE 11(12):e0163619, 2016. Correction: PLoS One 2018;13(5):e0197952.
Mason JW, Bellibas SE, Huang NY, Sanabria CR, Darpo B. Electrocardiographic effects of a supratherapeutic dose of oritavancin. Clin Pharmacol Drug Devel 5(6):502–8, 2016.
Mason JW. Which protocol should I use: The standard ICH E14 thorough QT/QTc study or concentration-effect modelling? Journal for Clinical Studies 8(6):68–71, 2016.
Mason JW. Antimicrobials and QT prolongation. J Antimicrob Chemother 72:1272–4, 2017.
Mason JW. Cardiologist's point of view: Novel ECG biomarkers and in silico models for proarrhythmic risk prediction; are we ready? J Electrocardiol 50:825–827, 2017.
Vicente J, Zusterzeel R, Johannesen L, et al. Mechanistic model-informed proarrhythmic risk assessment of drugs: Review of the CiPA initiative and design of a prospective clinical validation study. Clin Pharmacol Ther 103(1):54–66, 2018.
Kontogiannis C, Aravantinos D, Nanas I, et al. Salutary effects of the PULVAD, a novel implantable counterpulsation assist device, on left ventricular mechanoenergetics. ASAIO Journal 65(5):473–480, 2019.
Brockway M, Fossa A, Mason J. Comparison of two highly automated ECG algorithms for detection of drug-induced cardiac ion channel block. Clin Pharmacol Ther 104(2):359–63, 2017.
Macfarlane PW, Mason JW, Kligfield P, et al. Debatable issues in automated ECG reporting. J Electrocardiol 50:833–840, 2017.
Mason JW, Chugh R, Patel A, Gutte R, Bhatia A. Electrocardiographic effects of a supratherapeutic dose of WCK2349, a benzoquinolizine fluoroquinolone. Clin Transl Sci 12:47–52, 2019.
Vicente J, Zusterzeel R, Johannesen L, et al. Assessment of multi-ion channel block in a phase-1 randomized study design: Results of the CiPA phase 1 ECG biomarker validation study. Clin Pharmacol Ther 105(4):943–953, 2019.
Kinrade SA, Mason JW, Sanabria CR, et al. Evaluation of the cardiac safety of long-acting endectocide moxidectin in a randomized concentration-QT study. Clin Transl Sci 11(6):582–9, 2018.
Brockway M, Mason J, Brockway B. Comparison of electrocardiographic biomarkers for differentiating drug-induced single vs. multiple cardiac ion channel block. Clin Transl Sci 12:257–66, 2019.
Matsumori A, Shimada T, Nakatani E, Shimada M, Tracy S, Chapman N, Drayson M, Hartz V, Mason JW. Immunoglobulin free light chains as an inflammatory biomarker of heart failure with myocarditis. Clin Immunol 217:108455, 2020.
Matsumori A, Shimada T, Shimada M, Otani H, Drayson MT, Mason JW. Immunoglobulin free light chains as inflammatory biomarkers of atrial fibrillation. Circ Arrhythm Electrophysiol 13:e009017, 2020.
Matsumori A, Shimada T, Shimada M, Otani H, Drayson MT, Mason JW. Immunoglobulin free light chains as inflammatory biomarkers of atrial fibrillation. Circ Arrhythm Electrophysiol 13(11):e009017, 2020.
Mason JW, Strauss DG, Vaglio M, Badilini F. Correction of the QRS duration for heart rate. J Electrocardiol 54:1–4, 2019.
Sanabria C, Migoya E, Mason JW, et al. Effect of cefiderocol, a siderophore cephalosporin, on QT/QTc interval in healthy adult subjects. Clinical Therapeutics 41(9):1724–36, 2019.
De Bie J, Diemerger I, Mason JW. Comparison of PR, QRS, and QT interval measurements by seven ECG interpretation programs. J Electrocardiol 63:75–82, 2020.
Isart F, Mason J, Isart-Infante F, Ramos F. Surface electrocardiographic parameters of children and adolescents diagnosed with attention deficit hyperactivity disorder (ADHD) in an ambulatory community pediatric center. J Child Adolesc Psychopharmacology 31:227–32, 2021.
Kallend D, Mason J, Smith PF, et al. An evaluation of a supratherapeutic dose of inclisiran on cardiac repolarization in healthy volunteers: A phase I, randomized study. Clin Transl Sci 15:2663–72, 2022.
Matsumori A, Mason JW. The new FLC biomarker for a novel treatment of myocarditis, COVID-19 disease and other inflammatory disorders. The International Cardiovascular Forum Journal, accepted February 5, 2022.
Darwish M, Youakim JM, Mason JW, Stanworth S, Sanabria C. A phase 1, ascending dose study to assess the potential effects of trofinetide on QTc interval, safety and tolerability, and pharmacokinetics in healthy adults. Future Rare Diseases 5:1, 2025.
Mason JW, Romano SJ, Elliott GT, Mendzelevski B, Stanworth SH, Vaglio M, Badilini F, Gillings M, Riebman JB. Electrocardiographic effects of HBI-3000 (sulcardine sulfate), a new drug for termination of atrial fibrillation. Heart Rhythm O2 7(1):264–72, 2026.
Darwish M, Mason JW, Stanworth S, Feng X, Dirks B, Raether B, Pathak S. Analyzing the effect of ACP-204 on the QTc interval in healthy adult participants using phase 1 study data. Clinical and Translational Sciences, in press 2026.
Rasmussen H, Kurokawa K, Mason JW, Goodman DBP. Calcium, parathyroid hormone and calcitonin. Proc Fourth Parathyroid Conf, ICS #234, 1971.
Mason JW. Ventricular tachycardia induction in the selection of antiarrhythmic drugs. Practical Cardiol 4:120–137, 1978.
Bristow MR, Mason JW, Daniels JR. Use of the myocardial biopsy to monitor cardiotoxicity. Letter in Cancer Treat Rep 62:1067–1068, 1978.
Billingham ME, Bristow MR, Glatstein E, Mason JW, Masek MA, Daniels JR. Adriamycin cardiotoxicity: Endomyocardial biopsy evidence of enhancement by irradiation. 1978 Year Book of Cancer, 271–273, 1978.
Harrison DC, Mason JW, Simpson JB. Studies of the cardiac electrophysiologic and antiarrhythmic effects of acebutolol and its major metabolite, MB 16942. Proceedings of the Symposium "Beta blockade in clinical practice: Current trends," VIIIth World Congress of Cardiology (1978). WA Littler, ed. Amsterdam: Excerpta Medica, 85–91, 1979.
Mason JW. Anthracycline cardiotoxicity: Recognition, management, and avoidance. Compr Ther 5:64–67, 1979.
Mason JW, Billingham ME. Acute inflammatory myocarditis. Primary Cardiol 6:18–25, 1980.
Mason JW. The role of surgery in the treatment of arrhythmias. Hosp Pract 16:66–74, 1981.
Mason JW, Billingham ME. Acute inflammatory myocarditis. Physician Asst & Health Practitioner 16–20, 1981.
Mason JW. Review of "The Slow Inward Current and Cardiac Arrhythmias," DP Zipes, JC Bailey, V Elharrar, eds. JAMA 247:886, 1982.
Mitchell LB, Schroeder JS, Mason JW. Comparative clinical electrophysiologic effects of diltiazem, verapamil, and nifedipine: A review. Am J Cardiol 49:629–639, 1982.
Fowles RE, Mason JW. Myocardial biopsy. Mayo Clin Proc 57:459–461, 1982.
Winkle RA, Swerdlow CD, Mason JW. A look to the future: Outpatient placebo controlled trials of antiarrhythmic drug efficacy in patients with life-threatening ventricular arrhythmias. Symposium on New Drugs and Devices. Philadelphia: Martinus Nijhoff, 105–109, 1983.
Anderson KP, Mason JW. Surgical management of ventricular tachyarrhythmias. Clin Cardiol 6:415–425, 1983.
Gillis AM, Clusin WT, Mason JW. New horizons in antiarrhythmic therapy. J Cardiovasc Med 8:959–964, 1983.
Bristow MR, Billingham ME, Mason JW. Adriamycin cardiotoxicity. Am J Cardiol 53:263, 1984 (Letter).
Mason JW, Anderson KP. Treatment of ventricular arrhythmias. 2. Medical Therapy. In: Perspectives in Cardiology, 1984. B Sobel, D Julian, P Hugenholtz, eds. London: Current Medical Literature, 225–234, 1984.
Anderson KP, Mason JW. Les mécanismes de la tachycardie ventriculaire: les enseignements du laboratoire d'électrophysiologie. Le Journal International de Médecine, Cardiologie Mondiale, Editoriaux 12:11–19, 1984.
Fowles RE, Mason JW. Role of cardiac biopsy in the diagnosis and management of cardiac disease. Prog Cardiovasc Dis 27:153–172, 1984.
Mason JW. Endomyocardial biopsy: The balance of success and failure. Circulation 71:185–188, 1985.
Freedman RA, Anderson KP, Mason JW. Electrophysiologic studies in patients with ventricular tachycardia. Annu Rev Med 37:1–12, 1986.
Anderson JL, Mason JW. Criteria for selection of patients for programmed electrical stimulation. Circulation 73(suppl II):II-50–58, 1986.
Anderson KP, Freedman RA, Mason JW. The electrophysiologic study — when is it appropriate? Drug Therapy 16(6):111–126, 1986.
Anderson JL, Mason JW. Testing the efficacy of antiarrhythmic drugs. N Engl J Med 315:391–393, 1986 (Editorial).
Mason JW. Electrophysiologic study v Holter monitoring to assess cardiac drug therapy. J Critical Illness 1:12, 1986.
Anderson KP, Freedman RA, Mason JW. Sudden death in idiopathic dilated cardiomyopathy. Ann Intern Med 107:104–106, 1987 (Editorial).
Mason JW. Amiodarone. N Engl J Med 317:453–454, 1987 (Letter).
Freedman RA, Anderson KP, Mason JW. Tachycardia. In: Conn's Current Therapy. RE Rakel, ed. Philadelphia: W.B. Saunders, 198–207, 1988.
Mason JW, Moon TE. Treatment of ventricular tachycardia. N Engl J Med 318:1693–1694, 1988 (Letter).
Mason JW. Prediction of amiodarone-induced pulmonary toxicity. Am J Med 86:2–3, 1989 (Editorial).
O'Connell JB, Mason JW. Diagnosing and treating active myocarditis. West J Med 150:431–435, 1989.
Mason JW, O'Connell JB. Clinical merit of endomyocardial biopsy. Circulation 79:971–979, 1989.
Mason JW, O'Connell JB. A model of myocarditis in humans. Circulation 81:1154–1156, 1990 (Editorial Comment).
Mason JW. Distinct forms of myocarditis. Circulation 83:1110–1111, 1991 (Editorial Comment).
Mason JW. Endomyocardial biopsy and the causes of dilated cardiomyopathy. J Am Coll Cardiol 23(3):591–592, 1994 (Editorial Comment).
Mason JW for the ESVEM Investigators. The treatment of ventricular tachyarrhythmias. N Engl J Med 330(4):287–288, 1994 (Letter).
Mason JW. Predicting antiarrhythmic drug efficacy. Hosp Pract 29:28–35, 1994.
Mason JW. The US myocarditis treatment trial: Implications for treatment of myocarditis and its progression to dilated cardiomyopathy. Proceedings of the 3rd International Symposium of Advances in Cardiology and Cardiac Surgery III, Rimini, Italy, September 27–29, 1995. A Maresta, ed., 21–29, 1996.
Mason JW, O'Connell JB, McManus BM. Immunosuppressive therapy for myocarditis. N Engl J Med 333:1714, 1995 (Response to letters).
Mason JW. Arrhythmias associated with myocarditis. Cardiac Electrophys Rev 1:268–269, 1997.
Pisani BA, Taylor DO, Mason JW. Inflammatory myocardial diseases and cardiomyopathies. Am J Med 102:459–469, 1997.
Mason JW, Hlatky MA. Do patients prefer physiologic pacing? N Engl J Med 338:1147–1148, 1998.
Mason JW. Efficacy and efficacy testing of sotalol. J Am Coll Cardiol 33(1):53–54, 1999.
Mason JW. Amiodarone pulmonary toxicity and Professor Hounsfield. J Cardiovasc Electrophysiol 12:437–438, 2001.
Mason JW. Mindfully mining MUSTT. J Am Coll Cardiol 38:352–4, 2001.
Liu PP, Mason JW. Advances in understanding myocarditis. Circulation 104:1076–1082, 2001.
Mason JW. Viral latency: A link between myocarditis and dilated cardiomyopathy. J Mol Cell Cardiol 34:695–698, 2002.
Mason JW. Myocarditis and dilated cardiomyopathy: An inflammatory link. Cardiovascular Research 60:5–10, 2003.
Mason JW. The truth about shocking ventricular tachycardia and ventricular fibrillation. J Am Coll Cardiol 44:853–4, 2004.
Mason JW. Basic research on myocarditis: Superb but unrequited. J Am Coll Cardiol, doi:10.1016/j.jacc.2013.06.030, Jul 3, 2013.
Mason JW. The methadone menace. Clin Infect Dis, doi:10.1093/cid/cit469, Aug 14, 2013.
Mason JW, Billingham ME, Rider AK, Harrison DC. Myocardial biopsy. In: Clinical Cardiology, JT Willerson, CA Sanders, eds. New York: Grune and Stratton, 606–613, 1977.
Mason JW, Harrison DC. Electrophysiology and electropharmacology of the transplanted human heart. In: Cardiac Arrhythmias: Electrophysiology Diagnosis and Management. OS Narula, ed. Baltimore: Williams and Wilkins, 66–81, 1979.
Mason JW. Cardiotoxicity of quinidine and other type I antiarrhythmic agents. In: Drug-Induced Heart Disease. MR Bristow, ed. Amsterdam: Biomedical Press, 261–277, 1980.
Mason JW, Billingham ME. Myocardial biopsy. In: Progress in Cardiology. PN Yu, JF Goodwin, eds. Philadelphia: Lea and Febiger, 113–146, 1980.
Mason JW, Buda AJ, Stinson EB, Harrison DC. Surgical therapy of ventricular tachyarrhythmias in ischemic heart disease using conventional techniques. In: Medical and Surgical Management of Tachyarrhythmias. Heidelberg: Springer-Verlag, 177–182, 1980.
Stinson EB, Mason JW, Oyer PE. Surgical treatment of ventricular tachycardia. Chapter 33 in: Cardiac Arrhythmias: A Decade of Progress. DC Harrison, JW Mason, HA Miller, RA Winkle, eds. Boston: G.K. Hall & Co., 447–456, 1981.
Mason JW, Stinson EB, Derby G, Griffin JC, Winkle RA, Ross DL, Oyer PE, Harrison DC. Advantages of intraoperative activation sequence mapping for recurrent ventricular tachycardia. Chapter 39 in: Cardiac Arrhythmias: A Decade of Progress. DC Harrison, JW Mason, HA Miller, RA Winkle, eds. Boston: G.K. Hall & Co., 533–542, 1981.
Mason JW, Winkle RA, Griffin JC. Electrophysiologic-pharmacologic studies of ventricular arrhythmias: Evaluation of methods. Chapter 46 in: Cardiac Arrhythmias: A Decade of Progress. DC Harrison, JW Mason, HA Miller, RA Winkle, eds. Boston: G.K. Hall & Co., 631–642, 1981.
Griffin JC, Mason JW, Calfee RV. A programmable tachycardia terminating pacemaker for the treatment of arrhythmias. Chapter 27 in: Cardiac Arrhythmias: A Decade of Progress. DC Harrison, JW Mason, HA Miller, RA Winkle, eds. Boston: G.K. Hall & Co., 383–391, 1981.
Winkle RA, Mason JW, Harrison DC. Tocainide for drug-resistant ventricular arrhythmias: Efficacy, side effects and lidocaine responsiveness. Chapter 19 in: Cardiac Arrhythmias: A Decade of Progress. DC Harrison, JW Mason, HA Miller, RA Winkle, eds. Boston: G.K. Hall & Co., 285–296, 1981.
Harrison DC, Winkle RA, Sami M, Mason JW. Encainide: A new and potent antiarrhythmic agent. Chapter 22 in: Cardiac Arrhythmias: A Decade of Progress. DC Harrison, JW Mason, HA Miller, RA Winkle, eds. Boston: G.K. Hall & Co., 315–330, 1981.
Mason JW, Winkle RA, Swerdlow CD, Rasmussen K, Ross DL, Griffin JC. Pharmacologic therapy of ventricular tachycardia and the role of electrophysiologic study. In: Cardiac Electrophysiology Today. A Masoni, P Alboni, eds. New York: Academic Press, 315–323, 1982.
Mason JW. Left ventricular biopsy. Chapter 3 in: Endomyocardial Biopsy: Techniques and Applications. JJ Fenoglio, ed. Boca Raton: CRC Press, 15–22, 1982.
Mason JW, Billingham ME. Acute inflammatory myocarditis. Chapter 10 in: Endomyocardial Biopsy: Techniques and Applications. JJ Fenoglio, ed. Boca Raton: CRC Press, 79–85, 1982.
Billingham ME, Mason JW. The role of endomyocardial biopsy in the management of acute rejection in cardiac allograft recipients. Chapter 8 in: Endomyocardial Biopsy: Techniques and Applications. JJ Fenoglio, ed. Boca Raton: CRC Press, 57–64, 1982.
Mason JW. Indications for endomyocardial biopsy. Chapter 6 in: Endomyocardial Biopsy: Techniques and Applications. JJ Fenoglio, ed. Boca Raton: CRC Press, 45–50, 1982.
Griffin JC, Mason JW. Clinical experience with an automatically activated tachycardia terminating pacemaker. In: Cardiac Pacing. GA Feruglio, ed. Orlando: Grune and Stratton, 301–306, 1982.
Billingham ME, Bristow MR, Mason JW, Joseph LJ. Endomyocardial biopsy. In: Congestive Heart Failure. E Braunwald, MB Mock, JT Watson, eds. New York: Grune & Stratton, 237–251, 1982.
Stinson EB, Mason JW. Surgical treatment of cardiac arrhythmias. Chapter 11 in: Cardiac Arrhythmias: Current Diagnosis and Practical Management. RA Winkle, ed. Menlo Park: Addison-Wesley, 323–344, 1983.
Mason JW. Intracardiac electrophysiologic studies: Techniques and indications. Chapter 2 in: Cardiac Arrhythmias: Current Diagnosis and Practical Management. RA Winkle, ed. Menlo Park: Addison-Wesley, 20–45, 1983.
Winkle RA, Mason JW. Ventricular arrhythmias. Chapter 10 in: Cardiac Arrhythmias: Current Diagnosis and Practical Management. RA Winkle, ed. Menlo Park: Addison-Wesley, 290–322, 1983.
Mitchell LB, Mason JW. Encainide. In: New Antiarrhythmic Drugs. L Gould, ed. New York: Futura Publishing, 225–238, 1983.
Hondeghem L, Mason JW. Agents used in cardiac arrhythmias. In: Basic & Clinical Pharmacology. BG Katzung, ed. Los Altos: Lange Publishing, 158–174, 1984.
Mason JW, Swerdlow CD, Winkle RA, Ross DL, Echt DS, Anderson KP, Mitchell LB, Clusin WT. Ventricular tachyarrhythmia induction for drug selection: Experience with 311 patients. Chapter 13 in: Clinical Pharmacology of Antiarrhythmic Therapy. BR Lucchesi, JV Dingell, RP Schwartz, eds. New York: Raven Press, 229–239, 1984.
Echt DS, Mason JW. Management of serious cardiac arrhythmias with drugs. Chapter 13 in: Cardiovascular Clinics: Cardiac Drug Therapy. AN Brest, CR Conti, eds. Philadelphia: FA Davis, 191–209, 1984.
Swerdlow CD, Mason JW. Emergency treatment of ventricular tachycardia. Chapter 5 in: Cardiac Emergencies. MM Scheinman, ed. Philadelphia: W.B. Saunders, 89–110, 1984.
Anderson KP, Mason JW. Invasive electrophysiologic techniques in the diagnosis and management of cardiac dysrhythmias. Chapter 14 in: Acute Cardiac Care. DS Das Gupta, ed. Boston: Year Book Publishers, 268–293, 1984.
Mason JW. Acute myocarditis. In: Current Therapy in Cardiovascular Disease 1984–1985. NJ Fortuin, ed. Philadelphia: B.C. Decker, 90–92, 1984.
Winkle RA, Mason JW, Kates RE, Harrison DC. Encainide. In: Recent Developments in Cardiovascular Drugs. J Coltart, D Jewitt, eds. Edinburgh: Churchill-Livingstone, 102–109, 1984.
Laser JA, Fowles RE, Mason JW. Endomyocardial biopsy. In: Invasive Cardiology. JS Schroeder, ed. Philadelphia: F.A. Davis, 141–163, 1984.
Elson J, Mason JW. General concepts and mechanisms of ventricular tachycardia. In: Cardiology Clinics, Vol 4, No. 3. LN Horowitz, ed. Philadelphia: W.B. Saunders, 459–472, 1986.
O'Connell JB, Mason JW. The roles of endomyocardial biopsy and gallium 67 scintigraphy in the assessment and treatment of active myocarditis. In: Pathogenesis of Myocarditis and Cardiomyopathy. C Kawai, WH Abelmann, eds. Tokyo: University of Tokyo Press, 281–292, 1987.
Mason JW. Is there an ideal ventricular stimulation protocol? In: Ventricular Tachycardias from Mechanism to Therapy. E Aliot, R Lazzarza, eds. Boston: Martinus Nijhoff, 299–308, 1987.
Anderson KP, Freedman RA, Mason JW. Use of antiarrhythmic drugs: General principles. In: Cardiology. WW Parmely, K Chatterjee, eds. Philadelphia: JB Lippincott, 1–17, 1987. Updated 1991, 6.31–6.43.
Gilbert EM, Mason JW. Immunosuppressive therapy of myocarditis. In: Drug Therapy in Dilated Cardiomyopathy and Myocarditis. RS Engelmeier, JB O'Connell, eds. New York: Marcel Dekker, 233–263, 1988.
Freedman RA, Mason JW. Invasive electrophysiologic study. In: Progress in Cardiology 1/2. DP Zipes, DJ Rowlands, eds. Philadelphia: Lea & Febiger, 215–236, 1988.
O'Connell JB, Dec GW, Mason JW. The role of cardiac transplantation in patients with active myocarditis. In: New Concepts in Viral Heart Disease. HP Schultheiss, ed. Heidelberg: Springer-Verlag, 426–432, 1988.
Mason JW, Hondeghem LM. Principles of cardiac electrophysiology. In: Textbook of Internal Medicine. WN Kelley, ed. Philadelphia: J.B. Lippincott, 103–110, 1989.
Lee HR, O'Connell JB, Mason JW. Immunosuppression and beta-blockade in heart failure. In: Cardiology Clinics: Heart Failure: Current Concepts and Management. KT Weber, ed. Philadelphia: W.B. Saunders, 171–181, 1989.
Rawling DA, Mason JW. Programmed electrical stimulation after acute myocardial infarction. In: Modern Coronary Care. GS Francis, JS Alpert, eds. Boston: Little and Brown, 667–687, 1990.
Nappi JM, Mason JW. Quinidine. In: Drugs for the Heart and Circulation. FH Messerli, ed. Philadelphia: W.B. Saunders, 1193–1201, 1990.
Cooper MJ, Anderson KP, Mason JW. Invasive electrophysiological studies. In: Cardiac Electrophysiology: From Cell to Bedside. DP Zipes, J Jalife, eds. Philadelphia: W.B. Saunders, 837–849, 1990.
Mason JW, Anderson KP, Freedman RA, Rawling DA. Influence of underlying heart disease upon utility of electrophysiologic study. In: Cardiomyopathy Update 3: Restrictive Cardiomyopathy and Arrhythmias. EGJ Olsen, M Sekiguchi, eds. Tokyo: University of Tokyo Press, 161–164, 1990.
Mason JW, Hirota Y, eds. Heart and Vessels, Supplement 5, Proceedings of the International Symposium on Cardiomyopathy and Myocarditis. Tokyo: Springer-Verlag, 1990.
Freedman RA, Mason JW. Sustained ventricular tachycardia: Clinical aspects. In: Cardiac Pacing and Electrophysiology, Third Edition. P Samet, N El-Sherif, eds. Philadelphia: W.B. Saunders, 247–264, 1991.
Steinberg JS, Freedman RA, Bigger JT Jr, and the ESVEM Investigators. Antiarrhythmic drug therapy and the signal-averaged electrocardiogram. In: High-Resolution Electrocardiography. N El-Sherif, G Turitto, eds. Mount Kisco, NY: Futura Publishing, 569–590, 1992.
Mason JW. Cardiac arrhythmias and clinical electrophysiology. In: Adult Clinical Cardiology Self Assessment Program. RP Lewis, ed. American College of Cardiology, 5.3–5.31, 1993.
Mason JW. Classification of cardiomyopathy. In: Hurst's The Heart, Eighth Edition. RC Schlant, RW Alexander, eds. New York: McGraw-Hill, 1585–1590, 1994.
O'Connell JB, Mason JW. Inflammatory heart disease. In: Congestive Heart Failure: Pathophysiology, Diagnosis, and Comprehensive Approach to Management. JD Hosenpud, BH Greenberg, eds. New York: Springer-Verlag, 223–233, 1994.
Ensley RD, Renlund DG, Mason JW. Myocarditis. In: Cardiovascular Medicine. JT Willerson, JN Cohn, eds. New York: Churchill Livingstone, 894–924, 1994.
Anderson KP, Mason JW. Clinical value of cardiac electrophysiological studies. In: Cardiac Electrophysiology — From Cell to Bedside, Second Edition. DP Zipes, J Jalife, eds. Philadelphia: W.B. Saunders, 1133–1150, 1994.
Rawling DA, Mason JW. Programmed electrical stimulation after acute myocardial infarction. In: Coronary Care, Second Edition. GS Francis, JS Alpert, eds. Boston: Little and Brown, 669–688, 1994.
Mason JW. An interpretation of the ESVEM study. In: Progress in Clinical Pacing. E Santini, ed. Armonk: Futura Media Services, 791–798, 1995.
Mason JW. Cardiac arrhythmias and clinical electrophysiology. In: Adult Clinical Cardiology Self Assessment Program-II. RP Lewis, ed. American College of Cardiology, April 1995.
Mason JW, Buxton AE, Griffin JC, Hancock EW, Kennedy HL, Saunders DE, Schuger CD. Electrocardiography Self Assessment Program. American College of Cardiology, April 1995.
Taylor DO, Mason JW. Myocarditis. In: Cardiology. WW Parmely, K Chatterjee, eds. Philadelphia: JB Lippincott, 1–26, 1995.
Mason JW. Immunopathogenesis and treatment of myocarditis: The United States myocarditis treatment trial. In: Heart Failure: New Insights Into Mechanisms and Management. S Sasayama, J Ross Jr, DL Brutsaert, eds. Tokyo: Churchill Livingstone, 173–177, 1996.
Mason JW. Classification of cardiomyopathy. In: Hurst's The Heart, Ninth Edition. RC Schlant, RW Alexander, V Fuster, eds. New York: McGraw-Hill, 2031–2038, 1997.
Mason JW, Gettes LS, Griffin JC, Hancock EW, Kastor JA, Kron J, Saunders DE, Schuger CD. Electrocardiography Self Assessment Program-II. American College of Cardiology, November 1997.
Mason JW. Myocarditis. In: Advances in Internal Medicine, Volume 44. Schrier, Baxter, V Dzau, Fauci, eds. St. Louis: Mosby, 293–310, 1999.
Mason JW. Electrophysiologic diagnostic procedures. In: Cecil Textbook of Medicine, 21st Edition. L Goldman, JC Bennett, eds. Philadelphia: W.B. Saunders, 230–233, 2000.
Mason JW, Trehan S, Renlund DG. Myocardial disease: Myocarditis. In: Cardiovascular Medicine, Second Edition. JT Willerson, JN Cohn, eds. Philadelphia: W.B. Saunders, 1096–1124, 2000.
Mason JW, Compton SJ. Electrical disturbances of the heart: Long QT syndromes. In: Cardiovascular Medicine, Second Edition. JT Willerson, JN Cohn, eds. Philadelphia: W.B. Saunders, 1656–1664, 2000.
Mason JW. The electrophysiologic study versus electrocardiographic monitoring (ESVEM) trial. In: Arrhythmia Treatment & Therapy; Evaluation of Clinical Trial Evidence. RL Woosley, SN Singh, eds. Marcel Dekker, 50–74, 2000.
Mason JW. Classification of cardiomyopathies. In: Hurst's The Heart, Tenth Edition. V Fuster, RW Alexander, RA O'Rourke, eds. New York: McGraw-Hill, 1941–1946, 2001.
Mason JW. Treatment of lymphocytic myocarditis. In: Myocarditis: From Bench to Bedside. LT Cooper, ed. Totowa, NJ: Humana Press, 391–403, 2002.
Mason JW. Myocarditis. Chapter 15.8.1 in Oxford Textbook of Medicine, Fourth Edition. DA Warrell, TM Cox, JD Firth, EJ Benz, eds. New York: Oxford University Press, volume 2, 1017–1020, 2003.
Mason JW. Gene based therapy of long QT syndrome. Chapter 31 in: Cardiomyopathies and Heart Failure: Biomolecular, Infectious and Immune Mechanisms. A Matsumori, ed. Boston: Kluwer Academic Publishers, 429–438, 2003.
Mason JW. Inflammation and myocarditis. In: Inflammation and Cardiac Disease. GZ Feuerstein, P Libby, DL Mann, eds. Basel: Birkhauser Verlag, 315–323, 2003.
Mason JW. Electrophysiologic diagnostic procedures. Chapter 58 in: Cecil Textbook of Medicine, 22nd Edition. L Goldman, D Ausiello, eds. Philadelphia: W.B. Saunders, 2003.
Mason JW. Classification of cardiomyopathies. Chapter 75 in: Hurst's The Heart, Eleventh Edition. V Fuster, RW Alexander, RA O'Rourke, eds. New York: McGraw-Hill, 1883–1888, 2004.
Mason JW. Myocarditis. Chapter 59 in: Cardiovascular Medicine, Third Edition. JT Willerson, JN Cohn, HJJ Wellens, DR Holmes, eds. London: Springer-Verlag, 1313–49, 2007.
Mason JW. Myocarditis. Chapter 16.7.1 in: Oxford Textbook of Medicine, Fifth Edition. DA Warrell, TM Cox, JD Firth, eds. New York: Oxford University Press, 2758–64, 2010.
Mason JW. Myocarditis. Chapter 16.7.1 in: Oxford Textbook of Medicine, Fifth Edition. DA Warrell, TM Cox, JD Firth, eds. New York: Oxford University Press, Update 2014.
Mason JW. Myocarditis. Chapter 16.7.1 in: Oxford Textbook of Medicine, Fifth Edition. DA Warrell, TM Cox, JD Firth, eds. New York: Oxford University Press, Update 2017.
Mason JW, Schultheiss HP. Myocarditis. In: Oxford Textbook of Medicine, Sixth Edition. Oxford University Press, 2020.
Mason JW, Myers R, Stinson EB, Kriss JP, Alderman EL. Technetium pyrophosphate myocardial scanning in coronary artery bypass surgery. Circulation 52(suppl II):II-54, 1975.
Mason JW, Winkle RA, Ingels NB, Rider AK, Stinson EB, Harrison DC. Quinidine's electrophysiologic and hemodynamic effects in the transplanted denervated human heart. Am J Cardiol 37:154, 1976.
Mason JW, Specter MJ, Stinson EB, Ferris A, Ingels NB, Daughters GT, Alderman EL. The hemodynamic effects of acebutolol. Clin Res 24:86A, 1976.
Billingham ME, Bristow MR, Mason JW, Friedman MA. Endomyocardial biopsy findings in adriamycin-treated patients. Proc Am Assoc Cancer Res and ASCO 17:28, 1976.
Harrison DC, Mason JW, Winkle RA. Electrophysiologic action of acebutolol. Proceedings of the Seventh Congress of the European Society of Cardiology, Amsterdam, June 1976.
Ingels NB, Daughters GT, Specter MJ, Mason JW, Stinson EB, Alderman EL. Non-invasive measurement of the effect of intravenous isoproterenol on left ventricular dynamics in intact unanesthetized man. The Physiologist 19:238, 1976.
Koch FH, Billingham ME, Rider AK, Mason JW, Cipriano PR, Hancock EW. Pathophysiology of "angina" with normal coronary angiograms. Circulation 53–54(suppl II):II-23, 1976.
Billingham ME, Bristow MR, Mason JW, Daniels JR. Endomyocardial biopsy evidence of radiation enhancement of adriamycin cardiotoxicity. Circulation 53–54(suppl II):II-23, 1976.
Bristow MR, Mason JW, Billingham ME, Daniels JR. Endomyocardial biopsy and systolic time intervals in detection of adriamycin cardiotoxicity. Circulation 53–54(suppl II):II-80, 1976.
Ricci DR, Orlick AC, Reitz BA, Mason JW, Stinson EB, Harrison DC. Evidence for digoxin's direct action upon atrioventricular conduction in man. Clin Res 25(2):94A, 1977.
Koch FH, Billingham ME, Mason JW, Cipriano PR, Hancock EW. Pathogenesis of the click-murmur-prolapse syndrome: Biopsy evidence supporting an underlying cardiomyopathic process. Am J Cardiol 39:272, 1977.
Billingham ME, Bristow MR, Mason JW. Endomyocardial biopsy findings in patients treated with and without mediastinal radiation. Lab Invest 36:3, 1977.
Motta JA, Billingham ME, Guilleminault C, Barry WH, Mason JW. Cardiac electrophysiologic and histologic studies in myotonic dystrophy. Circulation 56(suppl III):III-217, 1977.
Anderson JL, Mason JW, Winkle RA, Meffin PJ, Fowles RE, Peters F, Harrison DC. Clinical electrophysiologic effects of tocainide. Am J Cardiol 41:415, 1978.
Anderson JL, Pope SE, Stinson EB, Mason JW. Protozoan infections following cardiac transplantation. Clin Res 26:124A, 1978.
Mason JW, Bristow MR, Billingham ME, Daniels JR. Studies of the identification, characterization, and amelioration of the cardiac toxicity of adriamycin in animals and man. 17th International Congress of Hematology, July 23, 1978, Paris, France.
Sami M, Oh G, Mason JW, Harrison DC. The electrophysiologic effects of encainide. Annual Meeting of the Canadian Cardiovascular Society, October 17, 1978, Vancouver, Canada.
Schapira JN, Meltzer RS, Alderman EL, Fitzgerald JW, Strunk BL, Popp RL, Mason JW, Barry WH. Quantitative evaluation of left atrial pressure-volume relationships in patients with aortic stenosis and atrial septal defect. Clin Res 26:269A, 1978.
Mason JW, Ricci DR, Billingham ME. Effective therapy for acute inflammatory myocarditis. Am J Cardiol 43:408, 1979.
Mason JW. Function of the denervated human sinus node. Am J Cardiol 43:388, 1979.
Sami M, Mason JW, Oh G, Harrison DC. Electrophysiology of encainide in the canine model. Clin Res 27:201A, 1979.
Sami M, Mason JW, Peters F, Harrison DC. Clinical electrophysiology of encainide. Clin Res 27:201A, 1979.
Mason JW, Peters F. Successful treatment of life-threatening ventricular arrhythmias with encainide. Clin Res 27:566A, 1979.
Mason JW, Winkle RA. Arrhythmia induction in patients with recurrent ventricular tachycardia: New findings. Circulation 60(suppl II):II-24, 1979.
Bristow MR, Mason JW, Billingham ME. Dose-effect and structure-function relationships in doxorubicin cardiomyopathy. Circulation 60(suppl II):II-44, 1979.
Jaillon P, Rubenson D, Peters F, Kates R, Mason JW, Winkle RA. Electrophysiology of n-acetyl-procainamide in man. Circulation 60(suppl II):II-63, 1979.
Mason JW, Winkle RA. Experience with tocainide for treatment of ventricular arrhythmias at Stanford University Medical Center. Presented at the Tocainide Workshop, Copenhagen, November 29–30, 1979.
Mason JW. Repetitive beating in response to single ventricular extrastimuli: Incidence and prognostic significance in patients with recurrent ventricular tachycardia. Am J Cardiol 45:407, 1980.
Griffin JC, Mason JW. Clinical use of an implantable automatic tachycardia terminating pacemaker. Clin Res 28:117A, 1980.
Mason JW, Peters FA. Antiarrhythmic efficacy of encainide in patients with refractory recurrent ventricular tachycardia. Circulation 62(suppl III):III-152, 1980.
Mason JW, Stinson EB. Comparison of efficacy of map-guided to blind myocardial resection for recurrent ventricular tachycardia. Circulation 62(suppl III):III-263, 1980.
Mason JW, Stinson EB, Ross DL, Bockemuehl K. Surgical therapy for right ventricular tachycardia. Am J Cardiol 47:497, 1981.
Winkle RA, Mason JW, Harrison DC. Encainide. British Heart Foundation Fourth European Symposium, London, July 21–24, 1981.
Echt DS, Berte LE, Clusin WT, Samuelsson RG, Harrison DC, Mason JW. Monophasic action potential effects of sotalol compared to propranolol. Circulation 64(suppl IV):IV-136, 1981.
Echt DS, Griffin JC, Ford AJ, Knutti JW, Feldman RC, Mason JW. The nature of inducible ventricular tachyarrhythmia in the chronic canine infarct model. Circulation 64(suppl IV):IV-217, 1981.
Ross DL, Davis KA, Alderman EL, Killip T, Mason JW. Ventricular tachycardia versus fibrillation in patients with cardiac arrest: Comparison of clinical, hemodynamic and angiographic characteristics (CASS). Circulation 64(suppl IV):IV-306, 1981.
Mason JW, Griffin JC. Assessing patients for tachycardia terminating pacemakers. Proc Ann Conf Eng Med Biol 23:177, 1981.
Griffin JC, Mason JW. Automatic burst pacemakers for reentrant tachycardias. Proc Ann Conf Eng Med Biol 23:180, 1981.
Swerdlow CD, Echt DS, Winkle RA, Ross DL, Griffin JC, Mason JW. Incidence of induction and drug prophylaxis of ventricular tachyarrhythmias: Dependence on arrhythmia type. Clin Res 30:21A, 1982.
Swerdlow CD, Yu JO, Jacobson E, Mann S, Winkle RA, Griffin JC, Ross DL, Mason JW. Safety and efficacy of intravenous quinidine. Am J Cardiol 49(Part 2):1043, 1982.
Mason JW. Efficacy of verapamil in recurrent ventricular tachycardia. Am J Cardiol 49(Part 2):1915, 1982.
Mason JW, Stinson EB, Oyer PE, Winkle RA, Derby GC. Mapping-guided surgical therapy of refractory ventricular tachycardia due to coronary artery disease. Am J Cardiol 49(Part 2):947, 1982.
Mason JW, Hondeghem LM, Katzung BG. Amiodarone blocks inactivated Na+ channels. Circulation 66(suppl II):II-292, 1982.
Swerdlow CD, Echt DS, Winkle RA, Mason JW. Determinants of survival in patients with ventricular tachyarrhythmias. Circulation 66(suppl II):II-25, 1982.
Swerdlow CD, Winkle RA, Mason JW. Prognostic significance of ten fewer induced beats during assessment of therapy for ventricular tachycardia. Circulation 66(suppl II):II-80, 1982.
Swerdlow CD, Echt DS, Soderholm-Difatte V, Winkle RA, Mason JW. Limited value of programmed stimulation in patients with unsustained VT. Circulation 66(suppl II):II-145, 1982.
Anderson KP, Stinson EB, Derby GC, Oyer PE, Mason JW. Vulnerability to ventricular arrhythmia induction in patients with hypertrophic obstructive cardiomyopathy. Circulation 66(suppl II):II-146, 1982.
Freedman RA, Griffin JC, Rothman MT, Mason JW. Safety and efficacy of an implantable automatic tachycardia terminating device. Circulation 66(suppl II):II-217, 1982.
Echt DS, Griffin JC, Ford AJ, Knutti JW, Mason JW. Inducible ventricular arrhythmias in chronic canine model using implanted devices. 7th International Symposium on Biotelemetry, August 1982.
Clarkson CW, Mason JW, Matsubara T, Moyer JW, Hondeghem LM. Slow inactivation in guinea pig ventricular myocardium. Biophys J 41:309A, 1983.
Freedman RA, Swerdlow CD, Winkle RA, Mason JW. Isoproterenol facilitation of ventricular tachycardia induction. J Am Coll Cardiol 1:671, 1983.
Connolly SJ, Mitchell LB, Swerdlow CD, Mason JW, Winkle RA. The clinical efficacy and electrophysiology of imipramine in patients with ventricular tachycardia. J Am Coll Cardiol 1:671, 1983.
Anderson KP, Stinson EB, Block P, Derby G, Oyer PE, Ross DL, Popp RL, Mason JW. Epicardial activation sequence mapping in hypertrophic cardiomyopathy. J Am Coll Cardiol 1:621, 1983.
Echt D, Swerdlow C, Anderson K, Mitchell L, Mason J, Winkle R. Value of adding extrastimuli vs shortening drive cycle length in ventricular tachycardia induction. VIIth World Symposium on Cardiac Pacing, Vienna, Austria, May 1983. PACE 6:A-141, 1983.
Griffin JC, Rothman MT, Echt DS, Freedman RA, Mason JW. Long-term follow-up of patients with an automatic tachycardia terminating burst pacemaker. PACE 6:A-142, 1983.
Keren A, Gillis AM, Freedman RA, Baldwin JC, Stinson EB, Simson MB, Mason JW. Heart transplant rejection monitored by signal averaged ECG in patients receiving cyclosporin A. Circulation 68(suppl III):III-151, 1983.
Mason JW, Stinson EB, Oyer PE, Winkle RA, Anderson KP. Arrhythmia mechanisms and outcome in surgery for recurrent ventricular tachycardia. Circulation 68(suppl III):III-176, 1983.
Bhandari AK, Shapiro WA, Evans-Bell T, Morady F, Mason J, Scheinman M. Electrophysiologic studies in the long QT syndrome. Circulation 68(suppl III):III-426, 1983.
Bhandari AK, Morady F, Shen EN, Schwartz A, Mason J, Scheinman M. Is left cervicothoracic sympathectomy effective treatment for patients with the prolonged QT syndrome? Circulation 68(suppl III):III-427, 1983.
Echt DS, Shapiro M, Miller J, Mason JW, Winkle RA. Oral lorcainide for sustained ventricular tachycardia and fibrillation. J Am Coll Cardiol 3:475, 1984.
Freedman RA, Gillis AM, Keren A, Soderholm-Difatte V, Mason JW. Signal-averaged ECG late potentials correlate with clinical arrhythmia and electrophysiology study in patients with ventricular tachycardia or fibrillation. Circulation 70(suppl II):II-252, 1984.
Nanas JN, Olsen DB, Hamanaka Y, Mason JW, Kolff WJ. Hemodynamic effects and biocompatibility of valveless implantable abdominal aortic counterpulsation device. Circulation 70(suppl II):II-306, 1984.
Swerdlow CD, Mason JW, Stinson EB, Oyer P, Winkle R, Derby G. Results of map-guided surgery in 103 patients with ventricular tachycardia. J Am Coll Cardiol 5:409, 1985.
Dorian P, Ford AJ, Davy JM, Meindl JD, Mason JW, Echt DS. Induced ventricular arrhythmias in a new chronic model of canine myocardial infarction. PACE 8:314, 1985.
Nanas JN, Mason JW, Yoshiyuki T, Chiang BY, Olsen DB. Superiority of an implanted abdominal aortic counterpulsation device designed for chronic use compared to intraaortic balloon pump. Circulation 72(suppl III):III-203, 1985.
Nanas JN, Mason JW, Yoshiyuki T, Chiang BY, Olsen DB. Hemodynamic effects of an implanted abdominal aortic counterpulsation device designed for chronic use on graded heart failure. Transactions of the ESAO, 12th Annual Congress of the European Society for Artificial Organs, Athens, Greece, September 1985.
Mason JW and the Amiodarone Toxicity Study Group. Toxicity of amiodarone. Circulation 72(suppl III):III-272, 1985.
Freedman RA, Swerdlow CD, Soderholm-Difatte V, Mason JW. Prognostic significance of arrhythmias induced at electrophysiologic study in cardiac arrest survivors. Circulation 72(suppl III):III-45, 1985.
Anderson KP, Lux RL, Nussbaum JA, Mannis D, Freedman RA, Mason JW. Dissimilarity in morphology of premature ventricular complexes and ventricular tachycardia. Circulation 74(suppl II):II-187, 1986.
Anderson JL, Askins JC, Gilbert EM, Miller RH, Keefe DL, Somberg JC, Freedman RA, Haft LR, Mason JW, Lessem JN. A controlled multicenter evaluation of sotalol for suppression of complex ventricular arrhythmias. Circulation 74(suppl II):II-311, 1986.
Nanas JN, Mason JW, Taenaka Y, Riebman JB, Olsen DB. Hemodynamic effects of an implanted abdominal aortic counterpulsation device after chronic use in animals. Circulation 74(suppl II):II-509, 1986.
Steinberg JS, Freedman RA, for the ESVEM Investigators. The signal averaged ECG does not predict drug efficacy in sustained ventricular arrhythmias. Circulation 76:IV-344, 1987.
O'Connell JB, Dec GW, Billingham ME, Goldenberg IF, Starling RC, Mudge GH, Augustine SM, Costanzo-Nodin MR, Hess ML, Hosenpud JD, Icenogle TB, Menlove RL, Mason JW. Results of cardiac transplantation in active myocarditis. J Heart Trans 8:99, May 1989.
Anastasiou-Nana MI, Menlove RL, Nanas JN, Mason JW, for the Western Enoximone Study Group. Spontaneous ventricular arrhythmia variability in patients with chronic heart failure. Circulation 80(suppl II):II-119, 1989.
Nanas JN, Anderson KP, Mason JW. Regional electrophysiological effects of intracoronary amiodarone. Circulation 80(suppl II):II-328, 1989.
Anderson KP, Ershler PR, Lux RL, Karwande SV, Gay WA, Urie PM, Runnels DE, Pace NL, Mason JW. Nonuniform electrical activation in idiopathic dilated cardiomyopathy. Circulation 80(suppl II):II-431, 1989.
McManus BM, Switzer BL, Kendall TJ, O'Connell JB, Mason JW, Myocarditis Treatment Trial Investigators. Markedly diminished natural killing and antibody-dependent cell-mediated cytotoxicity in patients with idiopathic dilated cardiomyopathy and biopsy proven myocarditis. Circulation 80(suppl II):II-666, 1989.
Freedman RA, Fuller MS, Steinberg JS, for the ESVEM Investigators. Effect of antiarrhythmic drugs on frequency-domain parameters of signal-averaged ECG. J Am Coll Cardiol 13(2):191A, 1989.
Greenberg FM, Dustman TJ, Fuller MS, Lux RL, Anderson KP, ESVEM Investigators. Initiation of spontaneous sustained monomorphic ventricular tachycardia. Circulation 82:III-580, 1990.
Sharp SD, Mason JW. Comparison of ST depression recorded by AM Holter and 12-lead electrocardiogram during coronary arteriography and exercise testing. J Am Coll Cardiol 17:168A, 1991.
Myocarditis Treatment Trial Investigators. Incidence and clinical characteristics of myocarditis. Circulation 84(suppl II):II-2, 1991.
The ESVEM Investigators. Determinants of a drug efficacy prediction in the ESVEM trial: Differences between electrophysiological study and Holter monitoring. Circulation 84(suppl II):II-348, 1991.
Mason JW and The ESVEM Investigators. Unsustained VT as a predictor of spontaneous sustained VT in the ESVEM study. Circulation 84(suppl II):II-348, 1991.
Anderson KP for the ESVEM Investigators. The Electrophysiologic study versus electrocardiographic monitoring trial. 58th Annual Meeting of the German Society for Heart and Circulation Research, Mannheim, Germany, April 23–26, 1992.
Caruso AC, Hahn EA, Marcus FI, The ESVEM Investigators. Predictors of arrhythmic death and cardiac arrest in the ESVEM study. Circulation 88:I-606, 1993.
Omoigui N, Marcus F, Mason J, Hlatky M, for the ESVEM Investigators. Effect of clinical and technical variables on initial hospital cost in ESVEM. Clinical Research 41:121A, 1993.
Omoigui N, Marcus F, Mason J, Hlatky M, for the ESVEM Investigators. Initial hospital costs in ESVEM. Clinical Research 41:234A, 1993.
Mendes LA, Picard MH, Dec GW, Palacios IF, Ryan TJ, Davidoff R, for the Myocarditis Treatment Trial Investigators. Left ventricular sphericity in active myocarditis. Circulation 88:I-599, 1993.
Reiffel J, Mann D, Reiter M, Freedman R, Huang SK, Hahn EA, Hartz VL and the ESVEM Investigators. A comparison of Holter suppression criteria for declaring drug efficacy in patients with sustained ventricular tachyarrhythmias in the ESVEM trial. J Am Coll Cardiol 23(2):279A, 1994.
Reiter M, Mann D, Reiffel J, Hahn E, Hartz V, and the ESVEM Investigators. Predictive value of combined Holter monitoring and electrophysiologic testing in the ESVEM study. J Am Coll Cardiol 23(2):279A, 1994.
Reiffel JA, Reiter M, Freedman R, Mann D, Huang SKS, Hahn E, Hartz V, and the ESVEM Investigators. Did the number of premature stimuli used or the length of unsustained tachycardia induced affect the predictive accuracy of the electrophysiologic study used to guide therapy in the ESVEM trial? PACE 17(II):826, 1994.
Hlatky MA, Boothroyd DB, Johnstone IM, Marcus FI, Hahn E, Hartz V, Mason J, for the ESVEM Investigators. Cost-effectiveness of alternative management strategies for life threatening arrhythmias in the ESVEM trial. Circulation 90(4):I-43, 1994.
Hlatky MA, Boothroyd DB, Johnstone IM, Marcus FI, Hahn E, Hartz V, Mason J for the ESVEM Investigators. Long-term cost of alternative management strategies for life threatening ventricular arrhythmias in the ESVEM trial. Circulation 90(4):II-339, 1994.
Reiter MJ, Mann DE, Reiffel JE, Karagounis LA, Hahn E, Hartz V, and the ESVEM Investigators. Reproducibility of drug efficacy prediction by Holter monitoring in the ESVEM trial. Circulation 90(4):I-178, 1994.
Lozano L, Wisecarver JL, Rubocki RJ, Wilson JE, McManus BM, and the Myocarditis Treatment Trial Investigators. HLA-Class II associations in patients with myocarditis. Lab Invest 70:129A, 1994.
Mendes LA, Picard MH, Dec GW, Palacios IF, Mahoney D, Davidoff R for the Myocarditis Treatment Trial Investigators. Discordance of right and left ventricular remodeling in active myocarditis. J Am Coll Cardiol 23(2):365A, 1994.
Mendes LA, Picard MH, Dec GW, Davidoff R, for the Myocarditis Treatment Trial Investigators. Early development of sphericity in active myocarditis: Association with left ventricular volume and function. J Am Soc Echocardiogr 7:S3939, 1994.
Anderson KP, Walker R, Dustman TJ, Fuller MS for the ESVEM Investigators. Spontaneous versus induced ventricular tachycardia in the ESVEM trial. Circulation 90(4):I-339, 1994.
Anderson KP, Mori M, Lyver S, Dustman T, Fuller MS, for the ESVEM Investigators. Mode of onset of spontaneous ventricular tachycardia and outcome in the ESVEM trial. Circulation 90(4):I-178, 1994.
Olshansky B, Hahn E, Hartz V and the ESVEM Investigators. Is syncope in the ESVEM trial a marker of cardiac arrest or all cause mortality? Circulation 90(4):I-456, 1994.
Anderson KP, Mori M, Lyver S, Dustman T, Fuller MS, for the ESVEM Investigators. Clinical characteristics and outcome of patients with ventricular tachycardia on the baseline Holter recording in the ESVEM trial. Circulation 90(4):I-339, 1994.
Reiffel JA, Hahn E, Hartz V and the ESVEM Investigators. Was the superiority of sotalol in the ESVEM trial due to its beta blocking effects? PACE 18(4)(II):811, 1995.
Olshansky B, Hartz V, Hahn E, Mason JW and the ESVEM Investigators. Out-of-hospital versus in-hospital death in the ESVEM trial. J Am Coll Cardiol (Special Issue):314A, February 1995.
Compton SJ, Lux RL, Ramsey MR, Strelich KT, Sanguinetti MC, Keating MT, Mason JW. Gene-derived therapy in inherited long QT syndrome: Correction of abnormal repolarization by potassium. PACE 19(4)(II):642, 1996.
Anderson KP, Mori M, Farig S, Gottipaty V and ESVEM Investigators. Improved outcome in patients with ischemic heart disease assigned to electrophysiologic study in ESVEM trial. PACE 19:618, 1996.
Li C, Shusterman V, Gottipaty V, Fahrig S, Anderson KP for the ESVEM Investigators. Changes in the energy distribution of heart rate variability in patients with chronic sympathetic predominance. PACE 20(II):1104, 1997.
Konety S, Shusterman V, Shah SI, Gottipaty V, Fahrig S, Anderson KP for the ESVEM Investigators. Dissociation in QT-RR relationship. PACE 20(II):1112, 1997.
Shusterman V, Aysin B, Gottipaty V, Fahrig S, Anderson KP for the ESVEM Investigators. Physiological saturation in the markers of sympathetic activity preceding spontaneous sustained ventricular tachycardia. PACE 20(II):1158, 1997.
Aysin B, Shusterman V, Grave I, Gottipaty V, Fahrig S, Anderson KP for the ESVEM Investigators. Differences in circadian variations of ventricular tachycardia and premature ventricular complexes. J Am Coll Cardiol 29:293A, 1997.
Shusterman V, Young L, Aysin B, Gottipaty V, Fahrig S, Anderson KP for the ESVEM Investigators. Heart rate variability preceding spontaneous ventricular tachycardia. J Am Coll Cardiol 29:472A–473A, 1997.
Anderson KP, Shusterman V, Aysin B, Fahrig S, Gottipaty V, ESVEM Investigators. Autonomic nervous system activity before PVC-triggered and non PVC-triggered spontaneous sustained ventricular tachycardia. Circulation 96(8):I-24, 1997.
Konety S, Shusterman V, Shah SI, Gottipaty V, Fahrig S, Anderson KP, for the ESVEM Investigators. Dissociation in QT-RR relationship preceding sustained ventricular tachycardia. Annual Scientific Sessions of the North American Society for Pacing and Electrophysiology, New Orleans, Louisiana, 1997.
Shusterman V, Aysin B, Beigel A, Brode S, Fahrig S, Gottipaty V, Schwartaman D, Weiss R, Anderson KP, for the ESVEM Investigators. Do slow variations in heart rate predict spontaneous initiation of ventricular tachycardia? PACE 21(II):948, 1998.
Shusterman V, Li C, Aysin B, Brode S, Fahrig S, Gottipaty V, Schwartaman D, Weiss R, Anderson KP, for the ESVEM Investigators. Circadian changes in the energy distribution of wavelet-transformed heart rate variability. PACE 21(II):887, 1998.
Compton SJ, Zhang L, Vincent GM, Timothy KW, Sanguinetti MC, Green LS, Lux RL, Mason JW. Adrenergic Ca++ and K+ currents in patients with KVLQT1 mutations. Circulation 98(17):I-776, 1998.
Zhang L, Compton SJ, Antzelevitch C, Timothy KW, Vincent GM, Mason JW. Differential response of QT and QU intervals to adrenergic stimulation in long QT patients with IKs defects. J Am Coll Cardiol 33(2A):138A, 1999.
Mason J, Compton S, Shepperd T, Pursley M, Burkhardt D. Gene-based therapy of inherited LQT syndrome. Cardiovasc Drugs Ther 15(I):27, 2001.
Mason J. The diagnosis of myocarditis: Past, present and future. Cardiovasc Drugs Ther 15(I):37, 2001.
Etheridge SP, Compton SJ, Pursley M, Burkhardt J, Shepperd T, Mason JW. Potassium shortens QTc in long QT patients with IKr defects. PACE 24:606, 2001.
Rambihar N, Jong P, McLaughlin PR, Butany J, Mason JW, Liu PP. Comparing long-term survival and frequency of heart transplantation in patients with suspected versus biopsy-proven myocarditis: A 15-year prospective follow-up. J Am Coll Cardiol 41:172A, 2003.
Matsumori A, Chapman NM, Tracy SM, Mason JW. Hepatitis C virus infection as a cause of myocarditis and heart failure. Circulation 110(suppl III):366, 2004.
Matsumori A, et al. N-terminal pro-brain natriuretic peptide as a marker of myocardial injury in patients with heart failure due to myocarditis and in health screening of individuals infected with hepatitis C virus. Circulation 112:II-600, 2005.
Mason JW, Morris S. Acute and chronic effects of PTH(1-84) on heart rate and cardiac repolarization in postmenopausal women with osteoporosis. J Bone Miner Res 21(Suppl 1), 2006.
Mason JW, Strachan I, Bloomfield DS, Tarrasenko L. BioQT improves standard deviation of QTc in definitive QT studies. Drug Information Association, Prague, 2007.
Guler HP, Li J, O'Farrell AM, Cherrington JM, Carter D, Mason JW, Boyea T. Dutogliptin, a DPP4 inhibitor, does not affect cardiac repolarization in a thorough QT/QTc study in healthy subjects. Diabetes, June supplement, 2010.
Howell JD, Mason JW, O'Mahony B, Donachie P. Cardiac safety of a granisetron transdermal system in the treatment of chemotherapy-induced nausea and vomiting. 2011 ASCO Annual Meeting, Abstract e19601.
Guillory G, Howell J, Mason JW, Donachie P. Cardiac safety of a granisetron transdermal system in the treatment of chemotherapy-induced nausea and vomiting. J Oncol Pharm Pract 18(5):14, 2012.
Bellibas SE, Huang NY, Sanabria C, Fusaro K, Good S, Darpo B, Mason JW. The effect of supratherapeutic doses of oritavancin on ECG intervals in healthy volunteers: Results from a randomized, double-blind, placebo- and moxifloxacin-controlled TQT study. Abstract A-1307, ICAAC 2014, Washington, DC, September 5–9, 2014.
Vicente J, Johannesen L, Afoakwa R, Pueyo E, Stockbridge N, Mason JW, Strauss DG. T-wave morphology assessment in a randomized double-blind crossover study of four hERG potassium channel blocking drugs. Circulation, 2014.
Johannesen L, Vicente J, Mason JW, Florian J, Galeotti L, Ugander M, Stockbridge N, Strauss DG. Improving proarrhythmic risk assessment of drugs: Combined retrospective and prospective clinical studies of 42 drugs. FDA Science Forum, 2015.
Vicente J, Johannesen L, Mason JW, Crumb WJ, Pueyo E, Stockbridge N, Strauss D. Comprehensive analysis of novel electrocardiographic device algorithms for differentiating arrhythmic risk. FDA Science Forum, 2015.
Vicente J, Johannesen L, Mason JW, Pueyo E, Stockbridge N, Strauss DG. Sex differences in drug-induced changes in ventricular repolarization. ISCE, April 13, 2015 (poster contest winner).
Wang Y, Haiyan L, Li Y, Guo S, Morganroth J, Mason JW, Liu J, Stockbridge NL. Lack of inter-ethnic difference in QT-susceptibility to moxifloxacin: Two independent QTS studies in Caucasian and Asian populations. 51st Annual DIA Meeting, Washington DC, June 2015.
Strauss DG, Vicente J, Hosseini M, Crumb W, Mason JW, Stockbridge N, Johannesen L. In vitro to clinical translation to improve proarrhythmia risk assessment. Safety Pharmacology Society, September 28, 2015, Prague.
Johannesen L, Vicente J, Mason JW, Florian J, Galeotti L, Ugander M, Stockbridge N, Strauss DG. Improving proarrhythmic risk assessment of drugs: Combined retrospective and prospective clinical studies of 42 drugs. FDA Science Forum Brochure 2015, 188.
Vicente J, Johannesen L, Mason JW, Crumb WJ, Pueyo E, Stockbridge N, Strauss DG. Comprehensive analysis of novel electrocardiographic device algorithms for differentiating arrhythmic risk. FDA Science Forum Brochure 2015, 195.
Mason JW, Chugh R, Lakdavala F, Bhatia A. Electrocardiographic effects of WCK 2349. ECCMID, April 9–12, 2016, Amsterdam.
Hellawell J, Zeng D, Patel K, Jochelson P, Blair C, Mason J, Belardinelli L. Eleclazine (GS-6615) attenuates QTc prolongation by dofetilide in healthy subjects. 2016 HRS Abstract PO05-163. Heart Rhythm 13(5S):S459, 2016.
Matsumori A, Shimada M, Shimada T, Tracy SM, Chapman NM, Hartz VL, Drayson MT, Mason JW. Elevated serum immunoglobulin free light chains in heart failure in the myocarditis treatment trial. ISCHF, December 2016.
Mason JW, Hugentobler E, Formella AE, Pope LE. Cardiac safety and QT intervals with DM/Q treatment: A review of clinical trial data. APA Annual Meeting, San Diego, May 20–24, 2017; Neuroscience Education Institute, Colorado Springs, CO, November 8–12, 2017.
Anand P, Mason J, Shakeri-Nejad K, Weitzman R, Wright A, Pandhi S, Legangneux E. Evaluation of effects of the novel AT2R antagonist EMA401 on electrocardiographic and hemodynamic variables in healthy subjects. EFIC 2017, European Pain Federation, Copenhagen, September 6–9, 2017.
Mason JW, Elliott GT, Romano SJ, Mendzelevski B, Allgren R, Gillings M, Roy D. HBI-3000: A novel drug for conversion of atrial fibrillation — Phase 1 study results. Abstract 11495. Circulation 140, November 11, 2019.
Paganoni S, Arnold SE, Hendrix S, Nicodemus-Johnson J, Dickson SP, Knowlton N, Timmons J, Manuel M, Badri S, Yeramian PD, Mason JW, Cudkowicz M. Safety of a fixed-dose coformulation of sodium phenylbutyrate and taurursodiol in amyotrophic lateral sclerosis and Alzheimer's disease: Integrated clinical trials experience. Abstract 131, AAN Annual Meeting, 2022.
Mason JW, Paganoni S, Badri S, Timmons J, Yeramian PD, Cudkowicz M. Independent expert review of cardiac adverse events and electrocardiographic abnormalities and parameters in a phase 2 trial of sodium phenylbutyrate and taurursodiol in amyotrophic lateral sclerosis (CENTAUR). International Symposium on ALS/MND, 2022.
Mason JW, Elliott GT, Romano SJ, Gillings MG, Riebman J. Sulcardine, an investigational multichannel blocker for atrial fibrillation with uniquely intense JTp inhibition to enhance safety. European Society of Cardiology Scientific Sessions, September 1, 2024. Eur Heart J 45(S1), 2024. doi:10.1093/eurheartj/ehae666.525.
Mason J, Roy D, Elliott G, Romano S, Pollack C, Gillings M, Riebman J. Sulcardine: Pharmacological conversion of AF with unique defense against excess QT prolongation. AHA Scientific Sessions, November 17, 2024.
Roy D, Romano S, Mason J, Wynn M, Pollack C, Elliott G, Gillings M, Reibman J. Safety and efficacy of HBI-3000, an investigational multichannel blocker for patients with non-permanent atrial fibrillation: Initial clinical findings. HRS 2025 Late-breaking Abstract.
Darwish M, Mason JW, Stanworth S, Feng X, Dirks B, Raether B, Pathak S. Analyzing the effect of ACP-204 on the QTc interval in healthy adult participants using phase 1 study data. AAIC, July 27–31, Toronto, 2025.